pleas introduc cowen europ best idea showcas analyst top invest recommend
among europe-list stock well list european compani addit washington
research group assembl thought europe-focus polici theme tariff trade anti-trust
regul artifici intellig also includ outlook environment social
governance-rel invest research team compil list top stock pick esg catalyst
europ best idea reflect cowen long on-going commit european client
unwav presenc thirti year legaci region grown stronger year
touch everi facet firmmarket invest bank invest managementand cours
european oper includ team profession market invest bank locat
eight european citi belfast berlin frankfurt leipzig london luxembourg munich zurich sinc
headcount europ
mani firm underinvest de-emphasize research effort cowen done opposit
invest resourc highlight innov collabor excel product like flagship
ahead curv seri demonstr commit agenda-set research research analyst
cover europe-headquart stock approxim compani deriv least
revenu econom critic region
dedic high level servic european institut investor past month
alon cowen host analyst meet day non-deal roadshow europ
today strong global invest bank platform abl execut cross-bord transact thank
januari acquisit significantli expand reach growth
market team lead execut clear settlement client transact countri
market worldwideenhanc acquisit convergex lead agency-focus global
brokerag trading-rel servic provid also significantli expand intern sale
trade recent addit team led matthew cyzer newli appoint chief execut offic
cowen execut servic ltd base london similarli achiev meaning scale prime servic
commiss manag algorithm electron trade clear extrem proud
cowen prime vote best boutiqu prime broker second consecut year hfm european
cowen mission help client outperform europ best idea one exampl put
promis action
thank continu partnership trust
chairman chief execut offic
impact requir polici respons monetari fiscal
author success respons set two-spe trade first half
defin slow viru demand impact second-half improv stimulu
measur take hold would benefit germani itali well auto resourc
financi sector second half
structur under-perform european indic past sever year rel
us dynam well document number reason
under-perform regim combin poor aggreg demand fragil bank
sector index construct lack secular growth constitu rel
develop market indic qqq kept region embrac global
alloc emerg viru result shock demand
potenti eas dynam present interest eurozon opportun
appropri respons coordin fiscal action becom realiti
come month fiscal space larg current account surplu countri germani
sourc content sever year balanc budget increasingli
difficult defend weight viru impact urgenc fiscal stimulu
becom appar result polic enact framework two-spe
trade build see first half domin digest virus-rel
demand shock second half rate chang beneficiari stimulu measur
index construct remain headwind european indic rel
us second-half recoveri led true fiscal stimulu drive mean revers
appropri fiscal respons viral demand shock benefit region
highest rate chang potenti germani itali best countri play
captur
sector level within sxxp rel perform auto sxap basic
resourc sxpp financi benefit fiscal-l recoveri
pleas see page report import disclosur
sxxp/spx eurostoxxx structur rel perform bear trend
sinc summer impact global economi unlik chang
near term howev market digest earnings/act impact demand shock
come month pressur european rel perform entri
point second-half recoveri trade like emerg forward earn expect
move target suspect forward ep multipl broader
sxxp prove attract risk/reward entri point begin look broad eu
index entri like present come month prior two
episod similar multipl contract absolut recoveri
index follow three month excess multipl level
show time concert fiscal effort launch contin
attempt work prevail rel perform trend vs
dax/sxxp fiscal respons emerg come month deal
demand shock situat rate chang potenti key focu
determin win regions/sector deterior german economi even prior
recent demand shock clearli evid captur expect full-year
estim estim start earli
revis lower time write potenti posit improv
german economi quit high appropri fiscal level get pull
see rel perform setup dax sxxp sinc
late germani lag broader european index break-out fail
weight viru uncertainti deterior like near term given
exposur german economi global demand second half recoveri
rel basi worth consid dax forward multipl move to/below
level defin low disloc attract entri
point emerg
ftse mib/sxxp italian market deal poor overal growth dynam
show better rel perform exhibit german dax
bottom rel broader sxxp key italian index
lowest full year outlook major eurozon economi
appropri polici respons viru emerg come month italian market
key beneficiari view second-half trade sideway
perform rel like view underli bullish trend
respect throughout process two-spe trade yield increasingli posit
rel perform second half year
sxap/sxxp import auto sector lag broader sxxp sinc
high set global synchron growth peak fail break-out
misguid reflat narr yield new rel low still take
time establish bottom bottom process occur rest
viru impact consumpt trend suppli chain calcul like take forward
multipl defin key low go back disloc two-
speed trade second half benefit auto rel perform key beneficiari
rate chang improv trade
sxpp/sxxp unsurprisingli growth concern contin global
pressur basic resourc complex pressur continu come
month demand impact relat digest before-
mention geographies/sector robust fiscal respons establish strong setup
rate chang beneficiari unambigu benefit basic resourc space
environ rate chang improv biggest
beneficiari european bank challeng sector structur
immens highest degre difficulti express play second-half
improv driven fiscal stimulu stimulu solv problem
help allevi pressur relat econom activ impact
bank system particularli deepli depress curv environ
long-end nomin respons better activ provid degre curv relief
tough environ eu bank system regardless polici respons
viru overhang howev believ second-half improv driven stimulu
make financi bang buck play improv
cowen compani llc
disclaim materi product cowen electron cowen electron market name use
electron trade offer oper cowen compani llc atm execut llc cowen electron
separ area within cowen inc physic electron barrier order inform
share access area cowen inc cowen electron share inform
third parti outsid regulatori bodi certain data may aggreg creat execut qualiti
metric post trade basi
materi product cowen compani llc cowen research depart
regard cowen research research report unless author clearli distinguish comment analysi
attribut cowen research analyst unless otherwis specif state view opinion express
herein sole individu author may differ view opinion express cowen
compani llc atm execut llc depart affili inform provid intend
provid suffici basi make invest decis
inform provid document provid use intend
recommend buy sell secur cowen electron make market hold posit cowen
compani llc affili may hold posit long short may effect transact make market
secur deriv secur issuer referenc document cowen compani llc
affili also may provid invest bank servic busi relationship issuer
mention herein data referenc herein time date referenc cowen electron
undertak oblig updat inform market price data inform warrant
complet accuraci subject chang without notic past perform indic
futur result invest discuss may fluctuat price valu transact financi instrument
mention includ option may suitabl investor
cowen compani llc member finra nyse sipc atm execut llc member finra sipc
elect trump wh scrambl contain
like littl done legisl wh like open new trade fight eu
may affect us militari sale eu bank merger may spur action us effort
eu regul boost homegrown tech firm unlik succeed dem wh like
wors drug maker manag care
go print today two stori domin headlin
enter critic phase elect outbreak
said past legisl tend happen odd year even year
campaign like differ window action close mid-jun
point washington empti campaign
fear cowen washington research group still plenti stori line watch
chri krueger note white hous like open new trade front eu
roman schweizer write trade disput europ may affect us militari
meanwhil propos european bank regul may spur new round consolid
jaret seiberg ask us bank join
paul gallant dubiou ec announc polici initi ai aim help
european compani catch us tech compani like googl facebook amazon
success
lastli cowen washington research group health care team look democrat
white hous could health care conclud threat drug maker greater
threat manag care plan
note cover european/washington assess polici team
materi intend
commentari polit econom
market condit
intend research report
defin applic regul
import disclosur
inform section report
risk brussel replac beij tariff tussl
summari thesi tariff halt edg pacif atlant theater
open aviat consum good agricultur energi crosshair
overal hard see avoid new tit-for-tat cycl retali major
threat investor risk anger presid impos long-threaten tariff
auto auto part exempt major non european trade partner seen
direct shot europ given focu re-elect unlik would happen
novemb elect though suspect like trump win re-elect
frustrat slow pace progress us-eu trade talk tougher line
new eu leadership also could contribut rise tension
least four open tariff front watch retali escal
airbus-rel wto tariff digit servic tax dst tariff retali climat
chang tariff eu wto seizur along new european commiss
leadership brought issu forefront
underappreci misunderstood structur issu washington
brussel london trump-centr steel aluminum tariff
trump-centr would like remov januari along retaliatori
tariff consum good democrat presid big three trade
issu bipartisan would issu hillari clinton jeb bush presid
agricultur subsidi market access nation champion policy/subsidi mainli
aviat digit servic tax europ defens spend lack thereof relat
nato anoth bipartisan issu cast shadow trade narr
earli march unit state trade repres publish negoti
object talk unit kingdom trade talk two track us-uk
us-eu agricultur major stick point chlorin chicken
march wto-approv airbu tariff increas european
aviat set kick-in soft deadlin aviat subsidi resolut dst
resolut mini deal us eu ustr also tariff variou
european consum good author rais tariff total
revenu per annum
novemb elect obvious big binari pivot improv eu/uk trade
relat grade curv democrat win versu potenti auto
bear case risk call actual bull case
mini deal european version china phase one reduc tariff industri good
clear bureaucrat obstacl trade food product work togeth develop
intern standard new technolog
summari thesi airbus-bo wto subsidi fight broader tariff
eu good couldnt come wors time hunt
coupl big german defens program would shore older product line
compani boe super hornet dogfight eurofight typhoon
airbu bae system leonardo replac germani tornado strike fighter
compani helo compet lockhe martin-rheinmetal team offer
replac german older model lot variabl
go source-select decis two german competit certainli political/
econom consider may come fortress europ defens industri
polici versu trump administr america first mantra promot weapon
sale abroad think domest eu polit intern trade could play major
factor mention grow franco-german collabor weapon program
could make eurofight home-contin pick lockheed/rheinmetall-l
team heavi german industri particip helo favorit boe team
german particip program due decid year plu
anoth long-delay program upgrad german patriot missil system featur
raytheon
underappreci misunderstood european/nato govern
increas defens spend bottom franc germani specif
havent buy hardwar much past appear
european defens money spent home system creat
new cycl european compani collabor program boe long-run
subsidi fight airbu trump administr tough trade stanc
europ could give germani reason need go european-heavi solut
catalyst mileston watch germani expect decid tornado strike-
fighter replac earli year aircraft buy bid germani
heavy-lift helicopt program decis made later year winner
build aircraft
bear case risk call struggl see -eu trade
issu get resolv anytim soon elect year trump white hous could
see economic/diplomat valu get sort novemb might
clear air allow compani better opportun
core nato/eu market one unusu compon fighter decis
eventu aircraft need certifi carri nuclear bomb someth would
reportedli easier super hornet typhoon sure that
enough factor tilt competit favor though regard heavi
lift helicopt incumb helicopt new king model extrem
expens think size sticker price sikorski issu develop
earli product lockhe sign german teammat may
come price german content
summari thesi believ polici pressur european bank
consolid short-term offer opportun merger produc winner
loser also design stabil bank system europ
posit econom growth long-term worri consolid creat bank
big fail big support european govern
get financi distress
catalyst mileston watch acquisit
first larg deal global system import bank unit state sinc
financi crisi transact scrutini washington congress expect
object regul pressur conduct exhaust review deal
expect get done seem like approv grudgingli question
unit state linger big fail bank
 trade even tradit bank region bank morgan stanley
want buy suspect outcri would much louder hurdl much higher
unit state may close big bank appear europ open see
largest financi firm combin order boost profit reduc expens
encourag come unlik sourc european central bank
recent stabil report discuss benefit euro area bank system
consolid
key point highlight report
euro zone bank simpli profit enough financi stabil report note
return equiti cost equiti report suggest
sustain blame legaci asset low interest rate environ
also structur problem high cost structur overcapac lack incom
stabil report argu signific overcapac lead unhealthi
market dynam weak competitor undercut healthier rival bid get enough
busi remain oper lead inabl bank earn fix
cost even cover variabl cost creat zombi firm hog capit
produc littl econom benefit
report argu structur chang must part solut poor bank
profit includ consolid could permit bank use economi
scale diversifi risk lower cost improv profit cross-bord deal may
offer effici may better diversifi risk creat
ecb said author need support consolid includ remov
barrier cross-bord merger stand contrast hostil
environ unit state
natur target would bank lowest profit ecb report said
quarter signific institut europ return equiti less
half median return equiti signific
institut europ under-perform bank tend come itali spain
germani report note
troubl bank elev cost-to-incom ratio report note
biggest smallest bank troubl cost
believ key line limit opportun diversifi busi model
wherebi effici bank may take restructur ineffici competitor
key recommend biggest bank insofar bank
viabl franchis cross-bord acquisit stronger bank possibl leav low-
margin legaci asset behind wind-down could solut offer revenu
diversif acquir
report acknowledg low market valuat may imped consolid also
said complet euro area bank union give boost
european deposit insur system uniform polici insolv tax
also regulatori restrict instanc cross border limit flow
capit liquid within singl bank could discourag deal make
also question could happen merg bank capit
requir consolid could lead automat increas g-sib capit
buffer report question whether increas would alway justifi
deal could make bank less riski diversifi incom
mean note follow
still real barrier europ bigger bank consolid
nation level countri unwil see champion bank bought foreign
bank regulatori issu one ecb identifi
particularli possibl boost capit requir
yet situat unit state europ could differ
feder reserv given indic will reconsid g-sib
surcharg despit signific industri pressur includ higher surcharg
relianc wholesal fund hear discuss need
consolid
anyth pressur unit state break bank hear
berni sander elizabeth warren seek
democrat nomin presid even presid trump previous endors
bring back glass-steagal act separ commerci bank trade
believ interest bank might europ
regulatori structur complex european central bank import
use clout set stage consolid
would suggest least profit european bank play acquir
strongest bank also would suggest ec less interest
merger among weak bank unless clear path diversif cost
short appear europ could get interest bank unit
healthcar polici weissenstein eric assaraf
summari thesi elect sen berni sander i-vt would unlik enact
medicar would like move shore reduc
uninsur would posit balanc manag care plan howev use
exist author sander could attack drug price even get congress
pass legisl make threat drug maker greater threat manag care
base upon posit paper candid focus two area possibl
chang drug price medicar includ lesser chang insur
case look two scenario sander white hous dem control hous
senat least like sander white hous dem control hous gop
senat like
sander insur market healthcar sander identifi medicar
singl payor plan would radic chang insur market main
propos sander plan includ
elimin privat insur
increas benefit includ long-term care dental vision
co-pay deduct except nomin co-pay drug
estim cost plan vari thorough analysi done
urban institut set increment cost feder govern trillion
sander drug price sander co-sponsor number drug price bill includ
bill would give newli creat board control launch price drug
bill give secretari hh author negoti drug price medicar part
maximum price index price drug five foreign countri drug
maker agre reduc price would give govern author
seiz patent drug sell anoth compani origin compani
would get fee new manufactur
believ would pass congress circumst sander bill
current co-sponsor senat companion bill hous
co-sponsor oppos plan hospit drug maker doctor
etc began inevit campaign kill
lack vote notwithstand sander control hous senat would
theori possibl pass reconcili problem plan
rule reconcili prohibit entitl increas cost money beyond
five year cover reconcili plan unless provis bill
fulli off-set out-year cost put mildli offset cost
year would difficult
would also like issu statutori pay-go rule requir cost
off-set budget window well prohibit extemporan measur
sander senat democrat could theori elimin filibust would
mean vote would need elimin filibust rel straight
forward procedur sinc senat rule law howev think
like presid trump call elimin filibust bipartisan group
senat wrote letter oppos idea
clear presid sander would focu first among mani mani
propos may loath start someth divis given take
major health care chang start administr past proven lead
loss first mid-term even unsuccess see clinton obama trump
bottom line even close accept ideolog democrat parti
opinion littl chanc enact
less drastic chang shore expand would like garner
signific major democrat would still bruis partisan fight
would like end chanc major insur reform exampl
might fund share reduct csr pool would like reduc
premium codifi silver load expand exchang subsidi lower incom
beneficiari give state expand medicaid higher feder match
rate sever year entic expans make cost share subsidi perman
public option cannib privat insur market would also like
without assent congress like noth sander could use
exist cmmi demonstr author cmmi demo budget neutral
base polici word off-set cost save elsewher
would doom demo
mean substant chang insur market use
sander would like seek immedi revers mani chang implement
trump administr among protect insur mandat
beneficiari protect like deni care pre-exist condit
reduc time beneficiari short-term plan
benefit plan would anoth exampl give state new money reinsur
program state exchang would like lower premium
medicaid waiver could use expand coverag revers trump administr
action would reduc coverag like work requir block grant partial
expans new popul waiver add new benefit could also like done via
bottom line see anyth done posit insur market
insur like sector insur market presid sander could
real effect individu market shore and/or expand individu
market would posit compani space
sander drug price plan sweep limit launch price direct negoti
target use exist author break intellectu properti protect certain
year proven enact sweep drug price chang harder seem
even parti use word
theori reconcili could use enact signific drug price chang tandem
insur reform exampl drug price reform would use pay
realiti would like harder seem signific major
democrat hous side howev vehicl exist senat probabl
bill would come closest pelosi plan would empow medicar
senior negoti drug price act introduc sen ami klobuchar d-minn
cosponsor democrat klobuch bill would allow direct govern
negoti drug price medicar prescript drug benefit among
chang oppos drug maker
passag bill allow direct govern negoti drug price would possibl
would need nearli senat democrat board less impact chang like
senat financ committe plan would stand better chanc passag tight
bottom line greater agreement among democrat drug price
make threat drug maker greater threat insur
opinion even direct govern negoti step far democrat
exampl thing could enact rebat part inflat cap
untangl ip protect increas medicaid rebat
drug maker could risk
sander could use cmmi demo author test chang drug price polici
medicar part plan would link reimburs vender medicar
part cost drug nation demo cmmi author
obama administr also propos medicar part demo cmmi
includ refer price chang strongli oppos drug maker
limit drug negoti move drug part part reform part
elimin incent use higher price drug modifi six protect class
part would exampl possibl effort use demo author
limit scope cmmi demo never test court difficult
say could could done sander administr mani way
power tool avail administr effect chang without assent
limit launch price drug would like possibl exist
author therefor would like need congress make happen
bottom line given difficulti get congress pass drug price legisl
would probabl biggest threat drug maker sander white hous
mani initi could get stall legal action remain signific
potenti avenu chang
underappreci misunderstood nearli sander propos chang
insur industri would requir congression action disrupt chang
would like need seat major senat
hand agenda drug price could done without congression
consent part plan would like strong support among democrat
hous senat
bear case risk call democrat win wave elect
democrat take signific number seat senat believ odd
low elect anyth possibl
summari thesi last month ec announc polici initi ai aim
help european compani catch us tech compani like googl facebook amazon
take reason european regulatori system
quit ambiti slow enforc hinder implicit explicit threat american
retali exampl gdpr googl anti-trust investig
exampl gdpr eu pass landmark privaci legisl rein
googl facebook creat new breath room european tech compani
facebook cfo recent said gdpr creat headwind compani ad target
europ facebook competitor seem fare even wors reason could
gdpr imped transfer user person data ad tech/publish run
ad campaign compet googl facebook gdpr take aim googl
facebook rule like data minim theori limit much user data
compani gather need perform particular servic
confid quit low regul ever enforc data limit
meaning way month gdpr began regul still havent resolv whether
googl facebook compli central user consent requir
exampl googl anti-trust investig ec competit unit led regulatori
rock star margreth vestag investig googl almost year
exactli shop android show shop issu
june underw oral argument court last month time court
rule even assum ec win five year end-to-end investig
compani take trade day admittedli part ec challeng
overstep hit us compani hard -- that alway understood
norm ec anti-trust trump actual delight punch back protect us compani
oversea franc champagn probabl sharpen us compani anti-trust protect
catalyst mileston watch skeptic europ craft new
round digit polici privacy/competition/ai boost european digit compani
key could whether us take hostil stanc toward tech
compani would open door europ here
ftc arguabl toughest ec action us tech
anti-trust rule us ftc win on-going
lawsuit could open season europ elsewher
ftc lawsuit strike heart model leverag chip strength
higher patent fee take feb oral argument
like prevail court either near-term circuit eventu pro-
 doj ftc investig google/facebook/amazon/appl think facebook
googl face lawsuit later signific potenti remedi
sought greater risk ec follow us lead even file lawsuit
would take long time play would like brand compani
monopolist could creat new polit vulner europ
 spotifi one except gener pro-u outlook europ tech polici
apple-spotifi ec investig aim benefit european music subscrib
pitch european compani spotifi cite european competit law
favor small compani us law key avoid
statement object essenti formal complaint ec there way
know one come receiv one signal like lose case
final rule come month later final point that great
commission vestag acknowledg mistak slow too-smal target ie
attack googl shop rather multipl vertic get
could accompani order immedi chang appl app store payment
system ec recent restart use interim measur immedi busi model
chang issu compani ec order interim measur part
last fall hope doesnt becom make-up case past
ec soft
report compil cowen best esg invest idea analyst
highlight potenti catalyst fundament stock recommend also merit
attent esg perspect continu see esg growth driven new fund
creation healthi inflow esg invest mandat awar heighten
larri fink letter ceo climat chang risk
pace esg portfolio integr acceler
integr posit environment social govern esg exposur portfolio
offer differenti alpha-addit complement fundament invest
analysi help attract retain grow pool asset fund manag growth
esg integr portfolio acceler recent year
strong increas asset manag number regist
invest compani incorpor esg decemb fund
invest manag implement esg invest criteria aum
equiti fund expect aum track index doubl
overtim exceed tradit index total sustain invest infrastructur
debt tax equiti equiti etc stood trillion accord report
global sustain invest allianc estim fund etf
focu sustain pull asset nearli accord
deloitt insight us sif foundat esg mandat repres activ
manag fund figur anticip rise
profession manag asset unit state us trillion
cowen compani us sif foundat
report compil cowen best esg invest idea includ
comprehens overview analyst stock merit attent
fundament esg perspect compani demonstr commend
effort incorpor esg principl core strategi busi model
outlin goal initi enhanc esg perform pleas see page
list cowen best esg idea follow addit detail insight
comprehens understand risk reward associ climat chang
critic investor assess portfolio risk-return profil compani
climate-rel exposur may materi shift due physic impact climat chang
climat polici new technolog chairman larri fink pen letter
ceo highlight climat chang januari note world largest asset manag
nearli trillion aum would avoid invest compani present high
sustain relat risk believ repres watersh event broader
order understand associ risk opportun climat chang pose
portfolio investor begin ask two simpl question
invest impact climat chang
climat chang impact invest
understand two fundament question help investor align environment
return financi return
investor call increas disclosur around esg issu
social respons invest longer nich issu climat chang concern
continu mount investor call public compani make increas disclosur
esg matter investor leverag intern extern resourc
screen compani esg attribut turn posit influenc corpor behavior
esg messag action esg integr systemat inclus
financi materi esg relat risk opportun number potenti
area focu esg investor gather inform exampl investor
focus environment impact fossil fuel may want understand
manag compani carbon footprint result emiss
esg invest
esg invest investment-rel activ account type esg
consider invest screen process separ asset class singl
strategi approach esg integr vari across investor esg integr
invest screen process becom mainstream numer new
fund open around theme well exist one leverag overlay process
accord februari report cere past year invest
focus esg issu nearli doubl one four dollar
invest esg len furthermor view two equiti non-
esg integr process screen ident around expect return risk
time investor would like choos invest equiti better esg profil
assum attribut two equiti ident
transport sector expos esg risk factor
effort combat climat chang invest opportun energi sector
pois acceler accord report task forc climat relat financi
disclosur transit lower-carbon economi estim requir averag
around trillion energi sector invest per year forese futur
recent announc dozen util aim net-zero carbon coupl
well bp plan fundament chang net zero target show
heighten carbon reduct initi due pressur stakehold sharehold
employe regul other
shift desir investor financi return environment benefit
motiv first sustain invest fund creat year ago
often religi ethic person valu meant fund sought avoid certain busi
alcohol tobacco gambl weapon exampl approach known
social respons invest fund employ strategi start
prolifer first social respons invest portfolio
creat actual church england may
earli earli period sustain invest character
neg select criteria howev tone buy-sid start chang toward
posit select criteria investig sustain score equiti
tradit valuat methodolog employ earli investor becam
awar among mani esg factor also number metric
highli financi relev period time financi analysi extend includ
environment social govern factor led concept esg integr
earli intens desir come new solut
combat global climat chang challeng idea themat invest came
forefront theme new fund rang sustain theme climat
chang water scarciti renew energi forestri today investor want
better understand ultim risk equiti portfolio face given acceler
climat chang trend industri expos increas headwind rel
other rang access capit issu avail resourc increas
regul investor aim financi return also want see
quantifi data impact invest societi want better
understand risk factor associ impact chang climat
demand invest offer posit environment benefit alongsid financi
return skyrocket recent year suppli themat product like green
bond sustainability-link loan esg fund activ passiv surg
respons rise esg invest also understood proxi investor
societi chang concept risk assess valuat adapt
broader societ chang
green esg sustainability-them fund
cowen compani bloomberg
decemb portfolio fund creat global around
theme consist billion asset accord data bloomberg
note includ separ manag account typic mirror fund
fund portfolio fund invest equiti debt use green esg
sustain screen portfolio repres trillion
total money invest broader clean energi sector domest asset owner tax
equiti etc accord report global sustain invest allianc
survey octob colleagu john kernan millenni reach
sustain valu ahead curv video indic
year old view social impact sustain brand purchas
decis import somewhat import well older
demograph averag regist older cohort within survey
 millenni consum asset manag like chang agent address
industri base low cost sourc gener signific amount
wast pollut note solar compani electr vehicl manufactur
repres top hold number account robinhood suggest
younger individu appli consum sustain prefer toward
cowen best esg invest idea
report compil cowen best esg invest idea highlight potenti
catalyst fundament stock recommend also merit attent esg
perspect addit attract fundament stock analysi stock includ
report reflect compani demonstr commend effort incorpor
esg principl core strategi busi model outlin goal
initi enhanc esg perform
comprehens list cowen best esg invest idea
cowen compani thomson reuter
price nametickerpricemarket cap mn rate price bergincomput servic consultingagil schenkellif scienc toolsalnylam baralbiotechnologyamerican line beckerlinesamicu rhyeemanag careappli sankarsemiconductor capit osbornetransport technologyastrazeneca plc scalapharmaceuticals/majoratla world-wide beckercraft leasingautomat data berginbusi servicesbak bianchioilfield servicesbiomarin nadeaubiotechnologychenier gabelmanu liquefi natur gaschipotl mexican silversteintelecom network rhyeemanag carecisco silversteintelecom network equipmentcv rhyeedrug retailersdanah schenkellif scienc toolsdelta beckerlinesedward jenningsmed devic synesaeldata centersfedex becker freight hannon osbornesustain energi industri technologyii-vi silversteintelecom equipment/wirelessinfineon osbornesustain energi industri technologylam sankarsemiconductor capit equipmentmicron yakosoftwaremonolith power system ramsaysemiconductorsnik kernanretail consum brandsnobl deckelbaumexplor productionnorfolk southern corp seidl railnovarti scalapharmaceuticals/majornucor kenyonsteelparsley energi daoudexplor azernon-alcohol beveragesroch hold ltd ramsaysemiconductorsstryk jenningsmed devic orthopedicst connect giordanodiversifi industri chenecommerc platformsthermo fisher schenkellif scienc toolstran khannamulti-industryunit rhyeemanag nadeaubiotechnologyvf kernanretail consum brandswabtec elkotttransport woodsoftwar cowen
analyst contribut sector
largest recycl produc steel unit state compani
steel mill oper util steelmak technolog convert recycl ferrou
scrap wide rang finish steel product servic divers set industri
end market steelmak product process consum recycl scrap less
energi intens offer variabl cost structur emit lower level
greenhous gase vs blast furnac steel product process time
compani strong cycl fcfe gener foster continu invest
innov steel manufactur reduc environment impact improv
employe safeti compani abil meet demand custom
requir recent embark capit invest plan aim
toward improv product mix lower convers cost employ
environment sustain process enhanc safeti benefit
invest begin manifest rate outperform price
target conserv repres fcfe yield ex heavi invest spend
forecast vs histor rang amid on-going volatil carbon
steel market attract nue strong defens characterist healthi
consist cycl fcfe low cost structur diversifi end market
product mix expect target organ invest next three year
add cycl ebitda minimum irr enhanc compani
cycl roic/fcf profil
invest manag solut freight transit rail
reduc fuel consumpt emiss compani highlight design
batteri electr locomot set integr diesel electr
locomot train hybrid train control compani
softwar significantli reduc fuel consumpt well
abil oper low emiss state popul area also
consid develop locomot transit servic oper zero
emiss environ tunnel extend period time
roughli one third global rail equip compani revenu compon
servic transit passeng railcar locomot infrastructur
remain two third freight locomot compon servic note
north america rail freight energi effici truck freight
manag like provid long-term growth goal march investor day
new york automation-rel digit revenu one sourc outsiz growth
anoth growth driver na freight locomot convers dc ac class
railroad continu implement precis schedul railroad expect
trough year railcar order deliveri posit cyclic turn potenti
begin late year continu
believ tel one best way coverag play three key mega trend
shift toward electrifi greener safer connect autonom
vehicl shift toward electr powertrain activ safeti analog digit
display requir higher level power data bandwidth transmiss
correspondingli demand tel content adopt advanc
factori build autom electrif everyth surg global
bandwidth demand usag drive demand high speed copper
fiber/opt applic densiti increas landscap continu built
tel special broad rang high-spe applic work
tradit equip supplier cloud-bas hyperscal player
tt remain top hvac stock share gain stori strong convers decent
balanc sheet moder rel valuat compani recent complet
spin-off industri segment re-nam pure-play
hvac climat compani enhanc esg characterist tt cite build
consum energi produc unit state third build
energi use come hvac tt recent announc aggress esg goal known
footprint one gigaton achiev absolut reduct energi consumpt
achiev carbon-neutr oper tt also target achiev gender pariti
leadership role upcom catalyst includ restat pf financi expect march
earn tt first earn post spin
railroad oper eastern portion truck-competit
part countri gener accept railroad fuel effici
truck implement precis schedul railroad upcom
catalyst share along implement drastic
differ oper model implement continu take shape
margin volum etc continu catalyst
addit convers highway rail truck recoveri serv
anoth potenti catalyst truck rate recov could caus
modal convers expens highway cheaper railroad
would posit
outperform-r standout coverag commit esg
initi began earnest launch perform
purpos program sinc continu taken step lessen
environment impact roll first all-electr deliveri truck
establish first compress natur ga fuel station current aim
sourc direct farmer sourc agricultur input sustain farm
vs meanwhil endeavor plastic
packag includ recycl content outperform-r stock non-
alcohol beverag frito-lay busi help allevi exposur
structur declin csd also provid avenu strong margin-accret
growth continu encourag pep esg accomplish outlook
still posit improv oper leverag trend model
consist top-lin growth oper incom growth near
good bad ugli although airlin accus larg
contributor climat chang carbon emiss aviat repres
total global emiss accord transport action group world-wide flight
produc million ton global human produc billion
ton aviat tourism industri repres mm job world-wide
account global
aviat respons emiss transport sourc
compar road transport transport carri less volum
world trade shipment high valu good repres
valu shipment
today aircraft fuel effici year ago
airlin fli three crew three engin aircraft replac
two crew two engin aircraft everi max replac classic ng
ceo fuel burn save addit industri use much
jet fuel today year ago industri bigger airlin fli
full vs averag load factor coronaviru
airlin park aircraft rather fli empti
last two decad airlin equip aircraft either winglet boe
aircraft sharklet airbu aircraft reduc fuel burn improv effici
chang aircraft improv fuel effici industri
current go anoth aircraft replac cycl reduc
emiss airlin commit reduc carbon footprint
level altern fuel avail airlin would use unit
airlin oper intra-california flight leav lo angel
airport non-fossil fuel addit entir ground support equip electr
battery-pow delta commit spend billion mitig emiss
across busi global refineri pipelin get
altern fuel market would convert manufactur altern fuel
product power aircraft
american youngest fuel-effici fleet north american airlin
spent billion last five year replac older technolog aircraft
american wont make anoth fleet replac decis
decid replac
american good corpor citizen commun provid free flight children
part make-a-wish foundat
american ceo take salari rather accept compens
form stock sharehold well well aal share
under-perform peer group varieti reason mechan contract
recent settl compani get back track year
delta take lead environ commit spend billion
next decad promot sustain technolog reduc carbon emiss
compani own refineri could convert manufactur altern fuel
pipelin get market
delta also work variou stem program around countri encourag
young peopl think career aviat program includ identifi
divers candid encourag scholarship pursu career
aviat mechan pilot
continu retir older three engin aircraft replac two
engin aircraft everi come servic replac
fuel effici improv depend upon jet fuel price
everi packag recycl program earthsmart enabl
integr sustain practic way work servic offer
custom compani use solar energi new facil continu
invest biofuel power aircraft ground continu diversifi
altern energi vehicl
atla score poorli area varieti reason major reason
relianc larg aircraft atla one world largest fleet four engin
said compani recent publish first corpor
respons report commit improv area
like chipotl commit food integr respons rais meat
produc coupl grow consum demand know what
food coupl improv qualiti board member
believ chipotl strike right balanc esg-rel invest
typic also serv bolster unit econom sharehold return
past year highlight invest behind item energi effici wast
reduct distribut optim drove tangibl esg benefit
support restaurant-level margin exampl compani instal energi
manag system across entir store base similar vein
reduc averag wast per restaur
wmt top three esg prioriti provid econom opportun
associ safeti livelihood worker suppli chain climat
chang look ahead wmt goal target includ achiev emiss
reduct wmt oper power oper
renew sourc energi sustain sourc key
commod addit wal-mart increas start
minimum wage hourli employe averag full-tim hourli
field total compens benefit increas
believ need continu prove compani sustain physic
digit comp come quarter furthermor investor look sign
compani keep e-commerc loss in-lin slightli better versu last year
maintain channel momentum leader groceri compani need
continu drive lsd msd categori growth take market share
leader luxuri resal market long runway growth brand
awar increas consum tri consign sinc found
off-set metric ton carbon save liter water
promot resal first compani take pledg ceo
carbon neutral challeng issu gucci ceo pledg carbon
neutral
compani address market larg untap expect gmv
growth high low rang near medium term expect
achiev profit platform leverag market sg
expens autom price copywrit photo retouch well outbound
nike move toward target high-singl digit revenu growth mid-teen
ep growth high-twenti low-thirti embed target
sever sustain goal includ limit transform manufactur
sourc factori meet definit sustain
minim environment footprint reduct averag environment footprint
score nike product sustain perform materi
increas use sustain materi sourc cotton sustain
energi emiss decreas emiss key oper textil dye
finish process wast reduc wast index cover footwear
manufactur water adopt new approach reduc water usag
suppli chain reduct freshwat use textil dye finish
build resili supplier water risk-mitig plan materi processor
enabl zero discharg hazard chemic nike publish sustain
commit annual impact report aim provid transpar
long-rang environment social goal nike previous set target sourc
renew energi global recent reach renew energi
across america within compani board director form corpor
respons sustain govern committe overse
pace sustain within nike busi strategi sever exampl
program develop implement nike nike grind program sever
decad old collect recycl shoe re-purpos apparel footwear
accessori applic retail store materi construct track field
construct compani convers renew initi use post-consum post-
industri wast creat new materi convers construct also nike
transform billion plastic bottl per year recycl polyest
jersey well materi apparel footwear compani
effort reach zero carbon/zero wast nike unveil new distribut center
belgium power renew energi compani report
footwear manufactur wast recycl contract factori
convert energi furthermor focu minim environment footprint
greater nike product score sustain perform
februari rais financ elig project design
contribut select sustain develop goal defin unit nation
launch traceabl map map end end traceabl nine-brand
expand brand next three year announc
sustain respons strategi made chang strategi commit
improv live suppli chain worker commun focus water
sanit health nutrit childcar educ compani set
goal sourc recycl nylon polyest product reduct
neg impact key materi commit use sustain cotton
procur cotton primarili us australia sinc compani use grow
method compliant better cotton initi help farmer reduc
environment impact improv farmer livelihood compani also continu
strive sourc electr renew sourc within own
oper facil zero wast intern distribut center
locat year end facil alreadi certifi name one
world ethic compani ethispher global leader defin advanc
standard busi practic see compound earn potenti reach
earn target impli low-mid teen annual ep growth
attract collect busi less exposur volatil capital-expenditure
compani of divis lever product chemic
artifici lift exposur secular growth build
turbomachineri divis share build provid solid
instal base aftermarket opportun construct compani strong
cash flow ramp current backlog drive ebitda improv absenc
restructuring/separ ge cash cost enabl signific inflect
model nearli attract
valuat trade unlev yield cheapest larg
cap of stock coverag valuat discount believ driven
overhang ge share ge still hold stake expect sell
year see best posit energi transit lower
carbon intens fossil fuel play key role transit
see compani jv combin ai iot bkr digit solut
divis key limit ghg emiss across energi suppli chain
oil ga explor product
parsley energi recent file corpor respons report highlight
among thing board diversif base countri origin gender
ethnic decreas ghg intens last year tree
plant texa off-set ghg emiss compani flare less
natur ga produc among best permian basin peer
pe remain well place deliv balanc growth model remain
support best-in-class resourc depth augment recent jag
acquisit watch updat ahead synergi captur drive well cost
lower enhanc gener support dividend increas
time
oil ga explor product
cash flow stori inflect significantli start-up leviathan
field off-shore israel support fix price contract grow demand
displac coal-fir energi israel region neighbor egypt jordan
accordingli de-emphasize onshor us growth allow
effici esg footprint increas return capit yield
also board refresh comp metric tie gener esg ad
new metric off-shore asset base provid uniqu cash flow profil
result expand yield come year also support smaller
lng sole busi convers us produc natur ga liquifi natur ga
lng export compani contribut adopt natur ga global
help displac carbon intens energi sourc coal oil
uniqu within energi given defens qualiti product capac tie
long-term take-or-pay agreement time growth opportun
compani favor posit provid us requir addit lng
export capac given first-mov advantag us lng product oper
track record pt base discount cash flow valuat methodolog
current oper expans construct one addit expans
expect sanction add liquefact capac
top idea auto tech believ compani portfolio featur
uniqu capabl hardwar softwar comput key next gen
vehicl platform believ secular shift automot industri
electrif autonom drive connect result oem
priorit spend creat opportun come earlier
design process help develop key electr data comput system
give compani leg futur product book well posit
key secular trend impact auto industri unlik peer
legaci busi structur declin trade margin growth
busi strong perform esg theme larg reflect compani
contribut toward mobil industri transit toward vehicl electrif
tackl environment aspect esg social govern
criteria compani vocal focu sustain divers
compens align object februari cecp ceo investor forum aptiv
highlight compani continu leader auto industri femal
represent women account workforc make progress
represent women manag revenu gener role
account manag posit revenu gener function
hannon armstrong one top idea believ compani well posit
continu execut grow pipelin end market continu work
believ compani increas compani see growth
market third straight year surpass transact target despit
pipelin remain core criteria hannon armstrong
sustain invest concentr around carbon emiss environment
benefit propos invest compani make must either reduc
neutral carbon emiss tangibl environment benefit
reduc water consumpt compani highlight everi invest
compani avoid metric ton cumul annual
avoid sinc million metric ton compani invest also
save billion gallon water cumul hannon armstrong portfolio
invest alloc debt equiti real estat across energi effici
sustain infrastructur wind solar clean water ecolog restor resili
project see hannon armstrong grow balanc sheet ep nice
follow portfolio rebalanc improv averag portfolio
yield expect compani continu achiev roe
itron portfolio smart network softwar servic sensor help util better
manag electr ga water resourc contribut compani strong
presenc esg theme itron product offer help mitig impact
challeng face energi grid stem digit transform
urban sever weather event integr renew energi sourc
compani core busi firmli align environment sustain goal
itron meter busi solut electr ga water help
util limit lost resourc better manag asset exampl case
treat water lost billabl custom ad intellig
system help identifi point loss improv util asset util ami
deploy increasingli use better accommod higher level
renew energi gener sourc like wind solar focus data analyt
grid intellig compani help custom increas uptim
reduc unplan mainten cost societ improv avail
util municip leverag entir smart citi system
good visibl given compani robust backlog north american
smart meter market larg evolv duopoli see well
landi gyr pois captur share upcom cycl announc
new contract award well addit restructuring/cost cut effort could serv
catalyst stock
amicu rare-diseas focus biotechnolog compani uniqu
patient-centr philosophi driven compani key leadership role rare
diseas drug develop social polici amicu also pledg limit futur
price innov novel therapi consum price index
consist price novel drug discount current therapi compani
develop program provid charit contribut help patient
profession nonprofit health care-rel organ deliv program servic
activ design enhanc live rare diseas commun
amicu develop therapeut rare orphan disord larg
unmet need compani deliv thu far success commerci launch
galafold fabri diseas see valu driven key updat
pomp program could constitut major catalyst share
regard esg focus initi alnylam goal larg around patient educ
nurtur awar learn rare diseas intern compani
promot volunteer divers inclus effort relat
environment object compani set target offer employe
benefit use public transport employe green seek way
reduc wast leverag environment respons program reduc carbon
manufactur corpor facil broader perspect alnylam one
health care compani publicli pledg limit price increas
therapi consum price index compani price philosophi focus
heavili provid net cost-sav health care system patient care
compani innov establish value-bas agreement
reimburs therapi link net price clinic valu provid
alnylam leader rnai therapeut recent success chang
dynam compani eye toward midterm profit two drug
market onpattro givlaari like two think alnylam pois
top-lin growth path toward profit
edward lifesci varieti esg relat initi underway led chief
respons offic compani recogn industri one
america compani forb capit nonprofit rank
largest publicli trade compani compani rate aa esg
rate recogn investor busi daili inaugur best esg
compani term sustain goal compani edward
varieti underway rang increas treatment rate sever aortic stenosi
patient reduc water usag solid wast dispos
convict edward multi-year multi layer sustain double-digit
revenu growth trajectori anticip stock momentum improv investor
sentiment driven quarterli outperform throughout view
setup full year highli favor edward tavr franchis
continu benefit low risk approv comp
zero low risk contribut view ew tavr growth guidanc conserv
thu see upsid top-lin consensu estim histor tavr
out-performance flow nice bottom line expect anoth year
meaning ep out-performance rel guidanc rang ew ep guidanc
rais cours ew multi-year estim ep compound-annual-growth-rate
stryker corpor respons initi center around promot global
health resourc effici improv safeti compani carbon disclosur
report rate compani aim improv rate multipl
avenu rang reduc wast everi manufactur plant part
key perform object emphas leed certif mani facil
compani pilot program shift transport need reduc packag
shift air ground and/or rail compani also partner hospit reduc
medic wast head landfil leverag collect singl use devic
hospit send back reprocess facil
enter come strong perform saw compani maintain
run deliv top-tier organ revenu growth vs med-tech peer group
expect streak continu throughout beyond compani continu
benefit momentum mako platform well broad strength across
divis includ medsurg neurotech spine also see upsid
manag organ growth guidanc believ prove
conserv especi set preced saw deliv
fall vertex announc creat posit head corpor social
respons overse varieti initi includ vertex commit
corpor give year start vertex
name barron sustain compani list forb best
employ divers latest csr report compani highlight
reduct energi goal boston headquart use baselin
compani presenc boston san diego particular lend public
transport usag bicycl thu report note employe use
method commut work lastli latest report note
workforc compris women workforc racial ethnic
vertex leader develop candid treat cystic fibrosi model
cystic fibrosi patient one vertex therapi drive almost
franchis sale base promis cf franchis project
revenu compound-annual-growth-rate non-gaap ep compound-annual-growth-rate
highest larg cap biotech
biomarin publish full corpor sustain report compani
highlight varieti initi around topic interest esg investor
compani promot green technolog across build leverag solar ev charg
water manag tool exampl compani chargepoint ev
charger bay area facil biomarin instal natur ga fire co-gener
system novato ca manufactur facil produc electr
use exhaust heat gener steam hot water
biomarin leader develop therapi orphan diseas dcf
worth approx biomarin pipelin among strongest mid-cap
biotech vosoritid valrox launch aggreg could
produc revenu
emphas compani aim build healthier commun lead
inspir growth employe custom supplier investor protect
planet csr report introduc account measur multi-
year perform target area target quit divers rang
declin new youth smoker rel water reduct goal
aim reduc empti mile deliveri truck fleet mile
rel baselin
posit long-term strategi coordin care combin
legaci asset aet broader health care system continu transit
toward value-bas care believ potenti bring differenti
model market gain share and/or improv profit
demonstr valu proposit market manag believ improv
outcom lower cost manag chronic condit use healthhub
leverag telemedicin nonphysician provid furthermor view share
under-valued current level valuat suggest market assum overli
roll-out healthhub locat realiz benefit
expect healthhub locat end healthhub locat
end catalyst share catalyst includ realiz
synergi cost save pbm sell season releas final
medicar advantag rate expect come april preliminari
rate alreadi releas expect compani realiz integr
synergi enterpris modern transform
initi expect net win realiz sell season follow
net loss sell season note compani alreadi complet
renew
produc corpor respons report year sinc call
connect latest report larg emphas whole person health highlight
initi goal reduc opioid overdos target
commun end regard environ compani aim
reduct energi facil water reduct note
pace exceed end
think ci stori rel straightforward oper execut
drive multipl expans solid guidanc reflect strong growth health
servic indic busi well posit sustain growth give
us confid ci abil achiev adj ep target ci
signific capit deploy option reach target leverag
ratio could use meaning increas dividend share
repurchas catalyst share includ releas medicar advantag final
notic expect come april well prime therapeut
onboard expect
unit health note sustain report litani metric rang
volunt hour charit give environment impact chang made
across facil compani implement low cost/no cost energi
water conserv project reduc energi use greenhous gase
compani creat task forc cut racial health dispar gap
greater columbu oh area list
jone sustain world jone north america rank
health provid servic sector compani name
unh domin market share health plan busi first-mov advantag
close integr health care servic busi provid compani
competit advantag expect continu grow least line
market health plan busi potenti exceed industri averag growth
rate notabl medicar advantag howev believ real growth stori
lie within compani optum segment optum grown aggreg
oper earn level integr uhc
optum enabl compani succeed payment model increasingli
shift toward value-bas reimburs catalyst share includ releas
medicar advantag final notic expect come april
multitud initi relev esg investor compani
join global initi bring togeth busi commit
sourc renew energi compani sustain report highlight
manag women benchmark program monitor
improv disclos inform carbon disclosur project ethispher
world ethic compani robecosam jone sustain
includ jone sustain
believ focu antm abil win extern pbm busi well
demonstr consist perform core health plan busi compani
expect ingeniorx gener annual run-rat cost save approxim
ep accru sharehold believ improv pharmaci
econom ingeniorx could enhanc antm competit posit
medicar advantag commerci risk market extern client win key
achiev antm long-term top-line growth rate annual
compani alreadi sign first extern client cross idaho went live
januari catalyst share includ releas medicar advantag final
notic expect come april
astrazeneca built sustain strategi around fundament pillar
access health care
ethic transpar
compani highlight progress area annual sustain
report latest edit compani note help train
health care worker global electr sourc renew
sourc staff senior middl manag higher women
azn promis new product pipelin particip mani larg high
growth market prospect could strengthen busi
development/partn ep growth appear among best industri
upsid possibl azn guidance/ambit deliv azn
progress dividend polici intact sum azn outlook one strongest
pharma argu purchas share
novarti file annual report progress around mani esg relat initi
novarti societi report edit highlight compani reduct
carbon footprint goal includ suppli chain term object
primari focu report increas access health care note
reach patient peopl reach train health
educ servic deliveri program
nv strength outweigh challeng strength includ entresto cosentyx
willing consid value-cr action potenti sandoz share
repurchas challeng includ roll-out kymriah increas competit cosentyx
sandoz struggl io strategi may may differenti ep
growth prospect appear averag
roch establish corpor sustain committe help investor assess
non-financi metric perform within compani compani follow
global report initi report gri guidelin sinc disclos
bevi esg relat metric data provid compani environment
impact detail varieti metric rang water consumpt ghg emiss
wast gener landfil inciner compani seen
decreas water consumpt decreas energi consumpt sinc
latest report highlight key leadership posit held women
promis new product provid opportun ep growth despit biosimilar
pressur fuel pe multipl expans pressur annual hemlibra
appear solid foot risdiplam hold signific promis ocrevu could garner
formid competit nv roch long histori innov
reason valuat strengthen invest case
regard esg initi agil name industri leader life scienc
tool servic jone sustain rank compani increas
invest sustain initi environment
compani abl achiev reduct greenhous gase sinc
seen wast divert landfil
agil revenu ep growth outlook peer group averag despit
compani growth outlook share continu trade ev/ebitda discount vs
peer agil higher exposur china rel peer group averag
repres risk continu like long-term risk/reward profil compani
believ share worth
introduc framework around philosophi regard sustain
center around innov peopl environ aim compani annual
sustain report provid measur result area go forward
edit sustain report highlight compani divers portfolio
product fight everyth sepsi quick detect hepat recycl
wastewat regard intern object report profil divers intern
well broader energi effici recycl initi across facil
expect revenu growth continu acceler deal
close confid compani top tier manag team
deliv strong conversionl believ cash gener enabl
compani rapidli paydown debt back market larger deal
thermo fisher provid investor corpor social respons report csr
year sinc highlight mani element relev esg investor
compani emphas divers work cultur inclus volunt within local
school organ well environment sensit ship practic
compani incorpor renew energi fuel cell batteri carlsbad
ca campu eindhoven netherland facil move renew
energi resourc leverag solar biomass wind energi electr aggreg
compani abl achiev reduct ghg emiss
reduct water usag thermo fisher also major global supplier test
equip use ensur environment food water safeti
thermo fisher scientif peer group averag revenu ep growth
outlook defensive-ori end market/product exposur top tier
manag team compani healthi balanc sheet cash flow support
 capac current view sourc meaning upsid rel
publish revenu ep expect
field work indic dram fundament may improv earlier expect
support mu improv cost posit vs peer mu nand cost headwind
known analysi show overal nand cost better fear nand
becom profit smartphon launch tighten suppli expect
benign memori price environ drive cyclic
improv profit cash flow memori produc limit memori capital-expenditure
year memori procur build buffer inventori respons sourc
materi construct facil leed gold statu higher facilit
environ team member divers commun key
sustain attribut micron
explicit leader esg initi messag action appear
leader among corpor citizenship recognit report vocal gender
equal aim gender pariti employe headcount
current workforc women strong represent top
includ ceo cfo see import divers initi right thing
also make good busi sens broaden appeal across broader pool
potenti talent compani ambiti environment initi aim
reduc carbon footprint commit renew energi usag
across oper
accentur digit leader earli aggress client rotat evid
higher valu servic call new account revenu see
path bp consist annual margin expans potenti larg driven
compani healthi oper leverag
strive social environment target stress gender equal
oper women encompass workforc commit
creat workplac environ empow work mother evidenc
inclus work mother best compani list multipl time term
environ adp current goal reduc emiss
deliv sustain top-lin growth believ compani margin
expans underappreci on-going commit transform
improv portfolio offer well custom servic believ
drive increas wallet share retent level
see infineon lead power semiconductor pure-play tie secular trend
across electr vehicl renew energi datacent power technolog
leadership high-voltag igbt mosfet emerg franchis gan
industry-lead manufactur scale believ infineon remain best
long-term pure play grow power demand effici end vertic
stmicro earli winner electr vehicl adopt continu invest
win emerg silicon carbid market stmicro expect silicon carbid
revenu increas least increasingli divers set
custom applic custom driven vast major growth
date howev st actual design win spread across custom split
roughli evenli across auto industri applic
monolith power thought leader power silicon space dynam
programm power manag expertis compani offer uniqu abil
combin core power/analog block lead digit memori function
proprietari bcd process see mp benefit win long-term
trend across datacent power automot electron
file annual corpor sustain report latest edit
compani highlight use renew energi across
global facil footprint addit compani commit publish
ghg reduct progress goal report diversif perspect
compani note new incom colleg graduat women
compani well expos upcom semicap memori cycl display
fundament turn around posit stock sentiment view
compani valuat attract
lam laid ambiti goal annual corpor sustain report regard
environ workplac safeti gender ethnic diversif use
baselin compani aim reduc ghg intens oper
reliant renew energi kwh energi save
upgrad light fixtur instal may led lam fremont
lam well expos upcom semicap memori cycl construct
compani strong cash flow gener attract valuat next catalyst
share lam analyst day march
take corpor social respons serious set forth
activ work third-parti vendor busi partner promot social
respons busi practic within busi within global
suppli chain end adopt principl set forth respons
busi allianc rba code conduct rba code conduct establish
standard ensur work condit electron industri suppli chain safe
worker treat respect digniti busi oper
environment respons conduct ethic promot principl
requir supplier adher standard also enjoy
sever notabl achiev includ great place work recognit name
fortun world admir compani develop inclus divers
initi includ black african heritag employe group
achiev gold star rate independ csr assess bodi ecovadi
revamp ciena care commun give program
also happen best idea within network commun
equip sector continu see benefit increas import
optic commun on-going share gain on-going revenu diversif
shift focu profit believ drive long-term growth
margin trajectori investor expect
cisco long histori corpor social respons launch
cisco network academi accord world largest longest-
run csr educ program set first greenhous ga ghg
emiss reduct goal achiev ghg supply-chain emiss
reduct target set new goal reduc supply-chain ghg emiss
cisco network academi partner educ
govern employ bring access digit skill million peopl
global equip student real-world skill career connect field
partner univers commun colleg even prison help bridg
shift convent job in-demand it-savvi job offer
curriculum partner free charg student
cisco network academi surpass goal reach million student per year
csr program includ collabor social invest partner
global citizen address global hunger well partner non-profit seek
end homeless silicon valley set goal achiev commun
impact particip amongst workforc measur volunt hour charit
donat particip program posit impact employe commun
instanc provid time employe volunt provid match
addit initi program describ note csco
on-going busi model transit higher margin software-bas revenu away
one-tim hardwar purchas ad benefit reduc global wast
importantli y/i revenu declin environ shift software-bas
revenu also improv resili csco oper model attend oper
cash flow investor focu remain csco growth outlook continu
see upward bia csco long-term margin structur believ drive
higher ep cash flow time
also take corpor social respons serious marque contribut
improv environ groundbreak research develop larger
size silicon carbid wafer key compon enabl electr
vehicl ev solar wind power smart-grid market iivi wafer
foundat energy-effici power amplifi built amplifi
turn critic develop ev drivetrain solar wind power turbin highli
effici high-voltag switch dramat reduc voltag loss smart-grid
exampl sic-bas power amplifi enabl drivetrain ev run
longer distanc without requir re-charg increas reach ev without
requir recharg significantli enhanc adopt ev moreov iivi
innov also driven total cost ev lower iivi contribut
develop larger mm-size wafer significantli reduc
cost develop sic-bas power amplifi ic sever thousand dollar
hundr dollar per amplifi reduct cost power amplifi
drive reduct overal cost ev greater
sever hundr power amplifi ev beyond innov iivi
marlow industri subsidiari ii-vi develop market thermal energi
harvest product significantli enhanc power consumpt therebi reduc
need battery-pow solut iivi product play key function reduc
wast energi convert residu energi electr dc power accord
energi conserv solut provid reliabl energi sourc
perpetu power wireless sensor microdevic lifetim harvest
offer low-cost zero mainten solut wireless sensor technolog
also commit sourc materi compani share enact uphold
higher valu human right ethic environment respons
end provid full transpar sourc miner use product
fulli compliant sec section provid transpar around
presenc conflict miner origin democrat republ congo drc
adjoin countri product manufactur contract manufactur
conflict miner necessari function product product
addit leverag number strong long-tail demand driver
includ euv aerospac defens manag team
demonstr track record except strateg vision strong tacticalboth
organ inorganicexecut
largest parti data center provid world revenu equinix
custom consum signific amount power turn compani
increasingli focus sustain april equinix rank epa
green power partnership nation top list reduc market-bas carbon
footprint global power consumpt
cover renew long-term
compani goal use clean renew energi across global
salesforc work integr sustain aspect oper key
guid object includ work toward renew energi
global oper continu deliv custom carbon neutral cloud
oper net-zero greenhous ga emiss compani part step
coalit commit includ sustain real estat new
major salesforc offic interior align leed platinum standard pursu
net zero carbon certif invest climat impact invest
climat entrepreneur startup advocaci collabor
lead geographi oper toward transit low-carbon
economi transport expand intern price carbon
offset busi travel employe commut emiss suppli chain
supplier emiss set emiss reduct target
water leadership commit mean busi improv
view attract invest consid strong execut track record
histor market share gain perform posit around high growth/high valu
segment softwar low valuat continu find crm risk/reward
profil attract trade sale
larg cap saa peer group trade respect
catalyst includ meaning synergi develop data improv
margin expans trend alongsid moder larg activ
commit achiev net-zero carbon emiss across offic
data center busi travel achiev net-zero carbon
emiss across offic data center global combin
oper effici procur renew energi equal
consumpt invest high-qual carbon off-set project provid
custom global carbon-neutr cloud support
develop clean energi project commit use renew electr
offic build data center also offset emiss
use natur ga offic build lastli wday multi-ten cloud architectur
help custom reduc busi cost carbon footprint central server
process optim energi usag elimin redund equip data
center optim process energi cool effici well use
renew electr europ data center run
execut well core hcm market year recent
make signific progress penetr newer market includ larg
enterpris financi analyt plan larg erp/financi system
one last major applic move cloud think tide chang
market adopt set elev year ahead strong
posit capit catalyst includ cfo suit product includ
financi plan analyt procur repres revenu today
sustain growth year come pipelin larg hcm opportun
strengthen rich set new product come pike
contribut meaning share trade sale
street estim larg cap growth peer view valuat
believ posit right secular growth market deliv
increment revenu also drive consist double-digit
earn growth overal migrat cloud remain earli day
expect azur particularli iaas/paa busi key beneficiari
ultim captur iaas/paa market msft mission
enabl everi company/individu start stop
technolog contribut compani commit carbon neg
plan complet remov environ carbon
compani emit either directli electr consumpt sinc found
despit msft incred success sinc satya nadella took ceo
expect share continu move higher reiter outperform pt
adjust ep cont oper
coronaviru eventu fade valuat contract lower
ep estim creat opportun given durabl brand posit
sport/culture/streetwear base case model ep stock price
histor valuat multipl novemb investor day catalyst approach along
emerg product cycl re-imagin franchis
adida posit sport health well global profession sport leagu fashion
cultur support durabl growth competit advantag shift digit
busi model reach sale vs support higher gross
margin/ double-digit ep growth approach all-tim high
model grow base/upside/downsid scenario suggest asymmetr
adida could achiev low-teen ep compound-annual-growth-rate next five year
includ mid-to-high-singl digit sale compound-annual-growth-rate ebit margin expans
proprietari survey suggest adida brand reson broadli across apparel
footwear activ view athlet cut estim adida
among millenni millenni interest streetwear confirm
sneaker altern asset class ahead curv video rapid growth
sneaker resal yeezi drive
releas ultraboost ultraboost catalyst contact suggest
impact innov brand sinc ivi park
yeezi continu scale anticip new five-year target
conjunct nov investor day see prospect new five-year adida target
support ep assum sale compound-annual-growth-rate ebit
margin expans driven gross margin expans
support dtc expand sale annual net incom
pt base ev/ebitda estim ep ev/
coronaviru risk includ demand destruct high-margin china suppli chain issu
rise consumer/investor uncertainti adjust estim lower assum
impact asiapac segment next six month recoveri
may conserv increas competit nike puma local
adida ag second largest sport brand world gener sale ttm
basi brand world global reach adida adida
potenti upsid consensu sale earn estim turn around
europ busi maintain momentum china america think adida
achiev low-doubl digit ep compound-annual-growth-rate next five year normal
oper margin narrow gap global athlet apparel footwear
report sale growth low-
ep price
oper margin deterior gm
contract sg de-lever
ep price target
adida ag second largest sportswear manufactur world follow nike
produc retail wide rang athlet footwear apparel accessori found
germani adida strengthen posit acquisit
reebok adida sell wholesal direct channel sponsor hundr high-
profil athlet athlet team world-wide multi-sport leader particular focu
footbal run basketbal adida also target street wear athleisur fast
fashion market adida origin yeezi adida label focus
perform technolog innov includ boost climacool
underappreci durabl brand
adida second largest sport brand world gener approxim
sale recent trail twelv month brand
nike global reach adida athlet space adida posit sport
health well global profession sport leagu fashion cultur support
durabl growth competit advantag shift digit busi
model e-commerc reach sale vs support higher gross
margin/ro double-digit ep growth see e-commerc unit econom
realiz full retail sale price increas ebit dollar realiz per transact
support higher approach all-tim high model
free cash flow grow see ebit margin reach low-to-mid-teen mid-
think adida achiev low-doubl digit ep compound-annual-growth-rate next five year
includ mid-to-high singl digit revenu compound-annual-growth-rate ebit margin
expans compani narrow gap global athlet
apparel footwear compani averag annual free cash flow approxim
pleas comprehens survey data estim price target
recent adjust model coronaviru impact asia activ view
athlet cut estim adida near term compani
report earn provid initi outlook think
would fallen in-lin consensu neg impact
adida manag expect issu new five-year target
conjunct novemb investor day first sinc base
case set new five-year adida target could support ep
approxim assum mid-singl digit sale compound-annual-growth-rate
oper margin expans driven gross margin expans
low double-digit net incom growth base case
outlook combin on-going share buy-back could support low-teen ep
compound-annual-growth-rate key driver top-line would continu digit expans
e-commerc revenu doubl target region sale cagr
western europ russia/ci tabl detail base case
target along potenti upsid downsid scenario
potenti upsid scenario could support ep reflect high-singl digit sale
compound-annual-growth-rate gross margin expans along modest sg leverag lead
oper margin expans high-teen ep compound-annual-growth-rate
cowen compani
releas ultraboost ultraboost catalyst contact suggest
impact innov brand sinc ivi park
yeezi continu scale adida announc earli april partner
beyonc knowl global signatur footwear apparel along re-
launch beyonc ivi park label announc met tremend
media coverag great anticip beyonc global reach signific follow
instagram follow help least bring addit
awar uniqu point view adida women offer accord
new york time articl link privat held ivi park activewear brand
introduc partnership topshop fulli own
beyonc sinc term adida partnership releas prior
sale data ivi park made public
price target base ev/ebitda estim
ep ev/sal see path double-digit ep free cash flow growth
driven adida strateg growth area continu ebit margin expans
estim adida gener free cash flow yield
acceler annual averag
base cowen estimatesupsid compound-annual-growth-rate compound-annual-growth-rate compound-annual-growth-rate group group group sale bs net sale bs net sale bs incom compound-annual-growth-rate incom compound-annual-growth-rate incom compound-annual-growth-rate work capitaloper work capitaloper work salescapex salescapex pay-out ratiodividend pay-out ratiodividend pay-out marginoper marginoper sale bs e-commerce sale bs e-commerce sale bs valuationassum valuationassum stock priceassum stock priceassum stock price irrupsid irrdownsid analysi cowen
compani report cowen compani
gross fit royalti commiss oper oper oper incom net incom continu losses/gain discont oper net incom attribut minor expens convert incom attribut sharehold continu ep forma non ep dilut share per share marginsgross chang royalti commiss chang oper chang oper chang oper incom chang chang chang tax chang yr /yrrevenu report basi incl currenc commiss oper incom oper incom continu oper per cowen
aercap ytd mostli due concern regard coronaviru compani
scale expertis balanc sheet navig challeng near-term environ
fact expect aercap capit current environ repurchas share
acquir asset struggl airlin long-term expect shift new asset
provid new opportun grow
rate common share aercap outperform posit bia due
compani proven abil manag challeng environ maintain
measur approach capit deploy aercap largest aircraft leas platform
world presenc scale balanc sheet allow act quickli
matter backdrop compani buy sell leas least one aircraft everi day
give deep insight market enabl spot trend react
accordingli increas demand mid-lif asset due oem product
delay new technolog aircraft aercap sell strength recogn
sale premium leverag return expect compani walk
bn sale estim throughout continu migrat fleet
new technolog aircraft compani use proce repurchase stock given
attract valuat coronaviru caus pullback aercap share expect
compani use step buy back stock suggest investor follow lead
aercap may look allevi balanc sheet stress struggl custom potenti
purchas aircraft shift asset part world demand remain
discuss aercap buy sell leas aircraft everi day activ
manag fleet give compani deep knowledg market current
aercap fleet measur book valu consist new technolog aircraft
max averag age year remain
aercap fleet current technolog aircraft
averag age year opportun next sever year shift
fleet new technolog aircraft oem product delay may slow convers
near-term boost asset valu leas rate exist technolog aircraft
natur migrat new tech aercap abil drive signific aircraft
gain buy back stock discount book aercap sold
part aircraft total proce bn gain sale mm
premium book time compani bought back bn stock
discount current book valu expect manag continu repurchas
share given valuat especi compani step sale activ
aercap one domin aircraft lessor world compani strong
backlog new aircraft deliv drive revenu book valu higher
aercap remain uniqu posit benefit global re-fleet airlin
activ manag fleet
leas rate see uptick due global
uptick global air traffic
capit continu flow industri
capit market dri
aercap leader aircraft leas own manag order
aircraft portfolio attract order book aercap serv approxim
custom roughli countri comprehens fleet solut
posit rate trajectori octob upgrad aercap bbb current aercap
posit outlook increasingli import move rate
scale lower cost capit aercap continu trend higher given scale
outlook abil execut
repurchas program sinc incept aercap share repurchas author
compani bought back bn stock expect compani
repurchas mm stock bn repurchas program make
sens compani consist sold aircraft book repurchas
share asset book valu
migrat new technolog aercap migrat new technolog aircraft
meaning way compani new tech aircraft fleet
end fleet tie aircraft shift swift
continu near-term despit delay oem shift asset
also creat opportun drive near-term earn aircraft sale middle-ag
potenti stabil wide-bodi market prior spread coronaviru
market made stride stabil wide-bodi market recent announc
reduc product month month earli remain
concern older sever bankruptci result aircraft hit
market time coronaviur run cours expect wide-bodi
market firm
coronaviru provid opportun coronaviru significantli impact global traffic
suggest impact china alon result traffic declin
prior forecast growth aercap approach situat
short-term headwind fact aercap might opportun purchas asset
struggl airlin china re-alloc plane market strength
reiter outperform rate common share aercap leav
price target unchang base book valu per share
estim aercap trade slightli higher forward price-to-book multipl three
year histor averag in-part due upcom acquisit aircastl
affili marubeni forward book valu find aercap book valu
underst due abil consist sell aircraft book
valu take leverag account given valuat anomali compani
continu find signific valu buy back share
forecast ep compar consensu
estim
thomson reuter cowen compani
two largest risk thesi near-term widespread impact
coronaviru oem product delay well past initi expect aercap gener
leas revenu airlin asia europ china
aercap indic will grant defer leas payment chines
custom view impact coronaviru temporari recent spread
viru itali caught market surpris concern spread
revis traffic growth lower due impact china
forecast traffic contract prior expect growth directli
impact china
delay airbu made challeng lessor properli grow
past sever year aercap look migrat fleet new technolog aircraft
includ neo aercap recent restructur orderbook
migrat like take longer expect posit side aercap benefit
tighter suppli push leas rate asset valu older aircraft
file mg strong driver see underappreci oppi itp
 cidp aml on-going md start jnj/argx cusatuzumab
highli promis model launch efgartigimod peak sale pt
base ep discount
believ argx lead candid efgartigimod anti-fcrn antibodi fragment
potenti best-in-class profil first mover advantag across sever indic
mg itp pv cidp offer iv sq formul efgartigimod eye
lucr multi-billion dollar market peak sale base peak share
mg itp po approv segment offer attract upsid
even consid potenti indic
autoimmun disord like mg itp pv cidp still unmet need despit avail
sever option steroid immunosuppress poor toler ivig
expens inconveni face capac constraint efgartigimod advanc
fcrn antagonist develop anticip posit data pv top-lin
sidam may mg well compani first bla file
efgartigimod mg drive stock appreci
also believ lucr partnership expedit develop
cusatuzumab antibodi current aml soon begin
high-risk md combin either vidaza venetoclax
argx also interest earli stage pipelin antibodi
commenc studi multifoc motor neuropathi mmn
deep pipelin multipl catalyst clear path near- long-term
valu creation stock ampl room appreci base data readout derisk
clinic mileston boost confid new indic opinion
argx perform well key overhang stock remain upcom data
releas mg space compet fcrn-target drug immunov
momenta vivacity-mg drug
appear well-toler previous shown upward knockdown
igg howev recent held ivig fcrn autoimmun diseas panel
annual healthcar confer also host firesid chat dinner
argx offer import insight competit autoimmun space
manag plan bring efgartigimod market
argenx appli novel llama-bas antibodi platform develop drug complex
target argenx efgartgimod antibody-bas therapi design satur fcrn
recycl pathway reduc serum level endogen pathogen igg autoimmun
diseas efgartigimod demonstr encourag data mg itp adapt trial
mg on-going advanc trial itp cidp base strong
data efgartigimod high probabl success across sever autoimmun indic
anticip drug highli competit lucr market cusatuzumab
partner base highli compel data aml stock could
offer investor attract return base deep pipelin focus novel target
initi first-in-human trial
top-lin data readout trial
initi aza/veneto combo trial
aml
initi aza combo trial high-
top-lin adapt efgartigimod data
file bla efgartigimod mg
success ph studi
success ph mg
continu show clinic
activ aml
develop success
expand beyond mg itp
success develop
fail ph trial mg and/
itp
argenx netherlands-bas biopharmaceut compani employ simpl antibodi
platform develop novel antibodi autoimmun cancer indic
efgartigimod anti-fcrn receptor antibodi multipl autoimmun indic
demyelin polyneuropathi cidp pemphigu vulgari pv cusatuzumab
antibodi aml partner antibodi
neurologist survey construct updat importantli model conserv
estim peak penetr refractori achr gmg market assum
presenc strong competitor equat roughli broader gmg market
interestingli survey neurologist conduct late feb ahead panel
discuss yesterday healthcar confer survey physician predict
weight averag gmg patient would receiv fcrn upon commerci
shown compar better safeti efficaci versu ivig survey mg
physician also expect upon approv fcrn inhibitor would like use
therapi steroids/immunosuppress ahead rituximab chronic ivig
itp survey also construct updat encouragingli feedback consist
survey hematologist treat itp also conduct late feb ahead
panel discuss yesterday itp specialist panel confer note
itp patient receiv chronic ivig therapi fcrn would almost certainli
given earlier ahead ivig fostamatinib given tpo receptor agonist
promin part current standard care fcrn antagonist use
interestingli survey physician feel itp patient treat fcrn
inhibitor would need show consist recoveri platelet count
readili adopt said physician also expect weight averag itp patient
would like given fcrn-target drug ahead ivig drug shown
compar safeti efficaci right line peak penetr
model efgartigimod refractori itp patient
attribut probabl success indic believ stock
appreci consider program yield posit data mg itp
signific lead develop would view addit posit data fast follow
fcrn antagonist addit proof mechan would valid
approach view posit tide would lift boat sizabl market
accommod sever player believ first mover take lion
share market
research consult consist enthusiast efgartigimod
virtu robust efficaci clean side effect profil without headach albumin
reduct avail iv sq formul lead market broad
develop four soon five indic henc drug beat
cusatuzumab promis aml md addit view argx/jnj cusatuzumab
antibodi offer anoth overlook opportun aml investor
gener skeptic aml therapi given poor prognosi mediocr efficaci
avail therapi narrow therapeut window seen
therapi develop howev earli stage cusatuzumab alreadi shown
highli synergist effect vidaza boost orr much
preclin data venclexta yield promis effect vidaza venclexta
standard care drug aml believ cusatuzumab provid upsid
program yield addit data aml high-risk md
argx intend initi trial complement inhibitor
would compani sixth clinical-stag program first ventur
lucr complement inhibitor space within manag note plan
build anoth pipelin within product compar efgartigimod pipelin strategi
year ahead novel mechan action target specif upstream effector
complement cascad offer way inhibit classic lectin-associ
pathway novel approach leav altern complement activ intact
would allow broader immun inhibit complement-associ disord
compar downstream-target drug like soliri inhibitor
expect posit pv data sidam may top-lin data on-going trial
pemphigu vulgari pv expect sidam may preliminari data
show fast onset respons median within week remiss rate reduct
pdai score combo steroid rituxan remiss rate onset
much faster rituxan take month note earlier studi rituxan
defin cr pdai score steroid use week notabl high bar
rituxan low-dos steroid treatment achiev durabl cr rate vs high
dose steroid alon rituxan alon achiev durabl cr notabl safeti
profil rituxan previou studi rel high rate sae show
develop diabet patient endocrin disord bone disord
cv disord myopathi incid infus relat reaction
headach henc efgartigimod anticip consist knockdown pathogen
igg reduct pdai like cleaner safeti profil versu rituxan support initi
pivot trial also expect key focu drug steroid spare
effect durat cr
expect posit mg data anoth major driver stock like
top-lin readout pivot adapt trial mg drug previous
show knockdown igg point improv mg clinic scale larger
improv competitor key function endpoint success
least partial factor stock posit data would solidifi
efgartigimod first mover advantag sizabl market expect posit data
support manag recent announc plan file bla expect
launch drug
firesid chat dinner manag firesid chat dinner argx
assert clear prioriti efgartigimod mg launch focu us filing/
approv first follow japan eu thereaft argx note preliminari
discuss japanes pmda suggest addit bridg studi would like
unnecessari approv discuss manag also shed import light
trial design lead indic aim develop clear dose
regimen drug label upon commerci
adapt studi mg design initi segment adapt trial
design random patient mg/kg efgartigimod notabl patient
stratifi without achr autoantibodi treatment cycl
includ weekli iv dose week follow week addit treatment
primari function endpoint assess proport achr patient
mg-adl improv least consecut week cycl follow
complet initi cycl patient enter time-vari inter-treat period
continu monitor weekli initi respond whose mg-adl score
rise back point elig begin anoth ident treatment cycl
relaps observ base criteria treatment time-vari inter-
treatment cycl pattern repeat mani time necessari durat
studi last cycl begin later day allow full cycl end
studi way studi assess durat respons interv
redos number treatment period
note although ultim show significantli higher proport
drug-treat patient achiev clinic meaning improv mg-adl
consecut week versu placebo primari endpoint measur
proport consecut week follow initi treatment admittedli
leav ambigu extrapol data trial design
importantli howev adapt studi also two open label extens
first continu main studi structur framework week allow
patient placebo crossov efgartigimod period use
dose scheme howev second ole leav redos long-term treatment
regimen physician patient discret allow taper background
standard care variabl well believ particularli ole shed light
extent frequent re-dos happen actual gmg clinic argx also
plan speak fda later year design bridg studi mg use
halozyme-partn enhanze-subq formul efgartigimod
advanc studi itp on-going patient advanc studi itp
trial dose patient placebo mg/kg efgartigimod studi primari
endpoint measur proport treat patient achiev platelet respons
 four consecut week six week smaller
confirmatori advanc studi patient assess proport treat
patient platelet respons week cumul addit
advanc studi explor util induc platelet respons itp patient
iv efgartigimod maintain respons use altern non-enhanz
subcutan formul differ sq formul itp mg
allow argenx differenti price indic manag note
commerci benefit develop multipl form subq efgartigimod particularli
use itp given narrow price rang indic offer
potenti price higher mg view offer upsid annual price
model
final argx/jnj cusatuzumab track begin sever combin trial aml
md addit on-going aml high-risk md schedul begin
argenx cowen compani
price target deriv multipl non-gaap ep estim
discount valuat assign probabl success
launch efgartigimod mg us eu itp us eu
consid success pv cidp upsid estim conserv model
peak penetr refractori patient global
argenx cowen compani
argenx financi model offer attract leverag everi addit market share
current assumpt would boost valuat mg itp
model annual price us ex-u price reason
may prove conserv given ivig soliri cost consider
autoimmun indic everi addit price efgartigimod would boost
valuat base sale mg base sale itp
thu despit stock strong perform recent month still view share
under-valued expect signific appreci late-stag program reach market
addit pipelin program progress clinic develop
highli competit landscap within mg autoimmun disord
investor skeptic efgartigimod wide adopt approv
case investor view market highli competit question extent uptak
mani investor question whether imbal background therapi
mg trial suggest posit result artifact imbal
disappoint mg data ucb rozanolixizumab rais question
potenti promis fcrn therapi mg view investor
howev base analysi mg data believ baselin
imbal use steroid immunosuppress account posit data
data show quick separ efgartigimod arm vs placebo patient
stabl background therapi enter studi consult note
quick separ vs placebo like due efgartigimod activ
factor account quick onset action henc expect stock
appreci data releas compet drug immunov
momenta provid valid approach
ahead efgartigimod data
consult fan efgartigimod would use wide mg
itp instead ivig even ahead current avail agent set
virtu clear efficaci clean side effect profil eas use like competit
cowen compani
cowen compani
profit shareoth oper oper oper rate tax incom ep option net tax net ep dilut profit shareoth oper oper oper rate tax incom ep option net tax net ep dilut cowen
reflect updat definit core financi measur exclud
intang asset amort charg impair except
is-rel intang
azn product momentum high rel growth unrecogn howev drug
stock characterist outperform extend period manag
execut opportun upsid forecast azn guidance/
ambit rel exposur make azn less vulner elect rhetor
attribut drive azn top perform
azn promis new product pipelin particip mani larg high growth
market ep growth appear among best industri upsid possibl
azn guidance/ambit deliv azn progress dividend polici
intact sum azn outlook one strongest pharma argu purchas
share
azn ambit product plu collabor revenu
factor currenc forecast consensu azn guid oper
margin low vs estim admittedli get
azn guidance/ambit manag execut well time stock
deliv high rel growth upsid time outperform multipl year
exampl univers
azn import news pharma stock includ enhertu
roll-out breast cancer pdufa roxadustat kidney failur associ
anemia eu approv lynparza brca pancreat /eu approv ovarian
mainten mcrpc fda action anifrolumab sle file tezepelumab data
asthma imfinzi neoaduv nsclc data opportun upward
revis sale ep growth prospect
target adr price base ep estim rich
multipl expect versu group overal howev pharma offer highli
visibl mid-teen ep growth model horizon believ azn premium
multipl justifi
pipelin disappoint alway possibl although mani key asset de-risk
azn could engag discretionari spend temper prospect may see littl
incent deliv ep growth well industri averag top line momentum
make clear azn underli strength elect rhetor could temper pharma
group perform higher multipl stock azn could clip disproportion
azn one least expos compani reform risk pharma histori
suggest multipl necessarili advers affect rhetor intensifi
azn promis new product pipelin particip mani larg high growth
market prospect could strengthen busi development/
partner ep growth appear among best industri upsid possibl
guidance/ambit deliv azn progress dividend polici
intact sum azn outlook one strongest pharma argu purchas
uptak new product notabl
tagrisso imfinzi lynparza fasenra
roxadustat approv china roll-out
full phase data imfinzi/trem
improv diabet respiratori
new product unabl sustain share
diabet respiratori franchis lag
astrazeneca biopharmaceut compani domicil key product area
cardiovascular diabet respiratori oncolog
time frameev ph data thale stroke patient posit top-lin jan ph data gastric cancer posit top-lin jan data nasal polyposisimfinziphas data neo-adjuv nsclc aegean phase data unresect stage nsclc tremelimumabphas data sschn kestrel phase data danub bladder cancerlynparza cediranibphas data ovarian data asthmatezepelumabphas data sever asthmaregulatoryanifrolumabregulatori file sle approv copdbrilintaregulatori file stroke patient thale /eu approv high-risk themis-pci calquenceeu approv cllenherturegulatori file gastric cancerfarxigau approval/eu file hf cv outcom pdufa approv cv outcomesimfinzi chemou /eu approv sclc caspian pdufa tremelimumabregulatori file bladder cancer danub regulatori file sschn kestrel lokelmajp approv hyperkalemialynparza w/mrk cn approv brcam breast canceru /eu approv ovarian mainten cancer pdufa approv brca/atm mcrpc profound pdufa approv brcam pancreat canceru file brcam ovarian cancerroxadustatu approv anemia pdufa w/mrk eu file neurofibromatosi type approv neurofibromatosi type pdufa file mild asthma cowen
compani data cowen compani estim
productcollaborationtotalgross otherop pretaxtaxnet ep y/ysharessalesrevenu chg report mm sl mm slsop inc dil divestitur interest divestitur interest retain payment diabet product impact core ep sg ar cowen
compani data cowen compani estim
despit multipl divest current manag success
transform slowli strengthen bausch portfolio launch multipl new
product across key salix dermatolog segment grow xifaxan
anticip modest stabl long-term growth allow debt-to-equ valu transfer
continu occur add
core thesi signific catalyst necessari tradit sens
believ method perform consist repay debt
necessari signific valu creation mean major catalyst via quarterli
oper disclosur clearli still except level debt manag
also scrambl reinvest develop portfolio meaning neglect
past team revers overnight importantli invest
acceler ensur consum therefor durabl
busi remain recent trajectori believ xifaxan durat look
safe thesi wealth transfer debt holder equiti
holder occur dcf indic per share sum part util fairli
conserv multipl see provid similar valu look anyth
heroic oper strateg perspect consist
cowen compani
provid durabl strong perform lumifi volum growth
biotru oneday ultra lens continu expans intern market
contribut stabl growth continu believ durabl franchis
underappreci under-valued
xifaxan promot cost structur optim clearli deliv xifaxan
revenu annual nearli y/i despit recent addit
gener challeng legal consult believ xifaxan patent durabl
least
signific opportun long-term growth driven mainli l/intern
salix launch duobrii forecast bausch revenu reach
modest ep growth assum tailwind growth xifaxan line growth
daili dispos biotru oneday contact lens normal duobrii
could off-set continu pressur diversifi segment ortho
sihi daili launch
success duobrii launch
threat xifaxan ip well
xifaxan ip beyond
averag growth l/
adopt duobrii trulanc low-cost
acquisit interest asset
earlier anticip xifaxan
gener filer mediocr perform
bausch health compani inc global diversifi specialti pharmaceut compani
develop manufactur market brand gener brand gener medic devic
over-the-counter product countri portfolio distribut across four franchis
dermatolog dermatolog medic aesthet devic diversifi product unit
neurolog genet dentistri product bhc success transform busi
target cost reduct restructur divest well payment long-term
debt renew focu leverag invest drive organ growth
disciplin debt repay provid growth opportun manag
guid repay debt oblig remain prioriti gener cash
flow analysi show oblig next year easili cover
current cash gener view durabl busi prove
accur plenti flexibl continu optim elong debt
increas invest ensur crucial l/int segment remain
innov par competitor durabl contributor divis key
discuss core thesi signific catalyst necessari
tradit sens believ method perform consist repay
debt necessari signific valu creation major catalyst via
quarterli oper disclosur signific focu duobrii launch expans
manag care coverag consist period debt repay xifaxan continu
volum growth launch sihi daili lens plan
indic discount cash flow model estim fair valu bhc share
bhc share current trade ebitda estim line
diversifi specialti pharma group howev given durabl core franchis
despit leverag believ bhc trade premium note
unlev compar alcon cooper compani roughli consensu
ebitda addit sum part analysi justifi price target util
ebitda multipl l/intern divis would signific
discount peer alcon/coop compani annual roughli
ebitda multipl salix divis in-lin median specialti pharmaceut
group annual ebitda combin ortho dermatolog
diversifi product in-lin gener manufactur annual roughli
yield enterpris valu roughli less net debt yield
equiti valu roughli per share price target
risk call includ challeng xifaxan ip gener inabl
refin increas durat debt competit threat vitamin and/or contact
len busi slower anticip launch uptak duobrii poor market
penetr sihi daili lens aqualox
cowen compani
lomb/assum new product launchesglob vision monthli legaci lens first launch daili dispos contactsbausch lomb lensesu sihi sept japan us launch global vision global vision surgicalanterior disposablesoth global vision global consum productsassum new product launches/offeringsocuvit len clean solutionbiotru multi-purpos len clean reliev eyedrop launch may global consum total global consum forecastglob optho gel reliev inflamm surgeri patent expir launch dec loe global optho global optho rxinclud sale canada europ asia australia latin america africa middl east brand pharmaceut product brand gener pharmaceut product over-the-counter product medic devic expect stabl mid-singl digit growth bausch lomb/ gener approv salix/gastroenterologygener cost structur growth loe settlement teva acquir uc loe expect signific drop revenu due loe loe march treatment uc loe reflux loe loe april prep co-promot us prep last qs salix azasantot june loe us pta invalid jublia patent aug file andaretina-a-micro launch quarter total formul patent psoriasi launch last patent ortho dermatolog ortho skin tighten launch asia pac canada emea textur global ortho health estim annual build-up mm cowen
cowen compani
gener approv diversifi productsneurolog otherlo wellbutrin gener launch juli diseas diseas diseas diseas neurolog diversifi pipelin product spend adjust xifaxan genericstot gross incom interest non-oper tax incom non-recur incom ep fulli ep non-recur dilut share health estim annual build-up mm cowen
cowen compani
lomb/glob vision lomb sihi global vision global vision surgicalanterior global vision global global consum product ocuvit multi-purpos global consum total global consum optho global optho global optho bausch lomb/ salix dermatologicsortho ortho dermatolog ortho dermatolog global ortho estim annual build-up cowen
cowen compani
product neurolog otherwellbutrin neurolog diversifi pipelin product total bausch incom interest interest incom non-oper tax incom ep fulli outstand fulli estim annual build-up cowen
cowen compani
assumpt sale net share outstand gross margin oper tax stock-bas work gener gener debt net debt ratio exit adjust ebita ebitdaimpli current multipl current evimpli target multipleimpli target evwith alcon/ multiplesimpli ev alcon/ health dcf exclud pipelin contribut cowen
landi gyr top european idea age us network wave rollout us/emea
mandat upgrad japan present multipl avenu growth share
pressur regulatori scrutini stall us sale howev believ investor
concern structur problem overblown see regulatori delay thaw
provid visibl landi
landi gyr core compet electr meter share north
america solid presenc japan select presenc europ compani
well posit capit impend need smart meter roll out refresh
see smart grid shift beyond meter opportun emerg cross sell
addit networking/saas-bas solut across distribut grid lead
margin expans see acceler regulatori decis smart grid expenditur
 favor landi name state ny nj other
also see addit state allow rate base saa solut outsid
ny il hi challeng addit major legaci year old network ca
tx pocket south like tender refresh suggest sustain
growth north american market regulatori delay us account
sale reason behind manag expect hit low-end
guidanc delay possibl linger howev see regulatori
delay temporari larg thaw provid visibl
continu regulatori scrutini pressur near-term sale believ
tradit european investor appreci full durat us electr
util rate base process lengthi drawn natur believ
number one question investor need clariti whether regul see fundament
problem smart meter delay by-product standard holdup
approv process investor appear view regulatori delay wit broader
smart grid space somewhat perman believ structur
problem caus delay american smart meter market delay
specif certain state see delay stem lack clariti around
clear articul benefit ami system consum energi effici
environ larg temporari expect regulatori decis ny nj serv
catalyst share come month
wait outcom evidentiari hear rate case
schedul commenc march also seek updat rate case
util experienc delay refil past year includ pseg
other near term catalyst share check suggest
new york well pseg alreadi select landi equip distribut
modern plan activ work state regul move forward
landi gyr play grid modern smart meter electr ga
water industri across north america emea apac util spend increas
portion capital-expenditure dollar improv transmiss distribut infrastructur
landi benefit manag execut sever restructur initi
acquisit grid edg intellig technolog well posit compani
profit softwar servic side busi backlog award project
grown recent year anticip traction manag servic saa
revenu acceler regulatori decis favor landi us legaci year old
network ca tx pocket south like tender refresh also
suggest sustain growth north america
outcom rate case decis
new york new jersey util
culmin cost cut effort
adjust ebitda north america
margin improv emea apac
emea approach adj ebitda
margin
gain us signific increas
favor regulatori decis
pace timelin
reduct fail materi
share loss north american market
rate case outcom us
unfavor landi
wave meter roll out
landi gyr group ag switzerland-bas compani primarili engag
electr compon equip manufactur compani special meter
solut electr ga heat/cold water energi measur solut
util landi product portfolio consist advanc meter intellig energi
manag product electr meter heat cool meter grid
compani offer variou softwar servic manag servic cloud servic smart grid
servic system integr train consult support servic among other
maintain outperform rate chf price target deriv use
multipl ep estim see close million meter
grab next month rang year old network like
modern southern compani austin energi other plu util seen
delay refil past year pseg dominion other north
american smart meter market larg evolv duopoli see landi
gyr along outperform pois captur share upcom
cycl see modern ami deploy crucial manag intermitt renew
energi gener longer term landi bevi new hardwar softwar solut
save util consum money
regulatori environ us fact structur issu pend rate
case get pass would see caus concern share howev
reiter view time statement util
well govern agenc state support view
regulatori delay specif state common rather concern part
util rate case timelin state undergo delay includ nm ky va ny
nj furthermor within state current million meter combin
form regulatori limbo also flag util earli
requir either resubmit applic pend approv
util repres meter us hand state
experienc delay broaden scope contract limbo believ
eventu get pass like compound investor concern near-term
propos util ami project statu
landi gyr capit market day cowen compani
dollar amount million except per share
good sold
research develop
revenu
sale market
revenu
gener administr
revenu
amort intang asset
revenu
divest
incom loss foreign exchang relat inter-company loan net
incom loss incom tax expens
incom loss non-controlling interest equiti method invest
net loss equiti invest
incom loss non-controlling interest
foreign currenc translat adjust net incom tax expens
pension plan benefit liabil adjust net incom tax expens
incom loss attribut non-controlling interest net tax
foreign currenc translat adjust attrubut non-controlling interest
net incom loss attribut landi gyr group ag sharehold
compehens incom attribut landi gyr group ag sharehold
select balanc sheet item statist
chang account receiv dec
chang account payabl dec
chang inventori dec
estim oper activ
depreci amort
compani data cowen compani estim
underpin sale price leverag tight distribut scale
momentum lvmh favorit european idea coronaviru may keep n-t valuat
bay potenti ep dilut
believ lvmh diversifi portfolio heritag brand geograph span coupl
robust global demand loui vuitton christian dior brand estimate revenue
strong gener key competit advantag see
potenti recent acquisit solidifi lvmh posit hard jewelri
categori reach beauti anoth categori like drive share
gain sephora perfum cosmet brand reach estimate
also acknowledg coronavirus-rel risk factor like yield neg ep
revis near term lower estim impli
growth vs prior near-term issu could lead pullback
next month see better entri point/buy opportun best
luxuri franchis note street ep estim current call growth point
refer sar price-to-earnings multipl contract point sale
organ asia ex japan constitut total vs
long-term valuat upsid convict stock base long-term valuat
upsid given consist market share scale like continu share gain
attract sector believ mid high price-to-earnings multipl appropri base
top- bottom-lin growth hsd sotp analysi indic pt
impli market capit vs today pt yield
dividend yield yield price-to-earnings vs averag
current valuat
lvmh posit outpac luxuri sector growth believ lvmh
well posit outpac overal luxuri industri growth per bain
capit robust growth outlook high net-worth individu expect
compound-annual-growth-rate chines consum expect drive major global
luxuri growth believ loui vuitton christian dior strong brand reson
propel lvmh growth industri averag also note
invest activ china last year lvmh expertis execut
help drive higher awar brand
luxuri sector resili luxuri sector demonstr resili
last recess luxuri consumpt rebound quickli drop sale
financi crisi lvmh sale decreas y/i recov
sale increas y/i note overal high-end luxuri sector less
prone promot substanti price power protect brand equiti
margin current model lvmh revenu growth hsd driven strength
fashion leather good watch jewelri categori sephora hsd
best-in-class luxuri long term rate lvmh mc fp outperform given like
lvmh brand geograph span high barrier entri best-in-class suppli chain
larg scale tight distribut free cash flow creation leather good brand power loui
vuitton estimate mix ebit margin growth jewel includ sephora
time view solid underli fundament combin consist growth
revenu profit drive ep upsid specif stabl hsd low-teen organ
growth improv luxuri consum sentiment asia
result may
lsd growth affect
coronaviru outbreak especi
oper margin contract
y/i
acquisit reflect
assum fx rate remain current level
coronaviru outbreak contain
earlier expect
oper margin loui vuitton
brand christian dior bvlgari brand
higher anticip
affect sale beyond spread
wide across globe
oper margin loui vuitton brand
lvmh luxuri good compani headquart pari sprung merger
moet hennessi loui vuitton sinc acquir numer brand achiev
leadership statur luxuri industri rang champagn leather perfum
diamond aggreg lvmh earn revenu wine spirit
fashion leather good perfum cosmet watch jewelri
select retail asia lvmh largest market contribut nearli third
compani revenu repres total revenu franc provid
figur histor forward cagr reflect cowen estim
compani report cowen watch jewelri includ
brand innov new gener loui vuitton forefront
luxuri streetif casual activ innov across categori lv
men creativ director virgil abloh instrument increas brand
relev younger gener shopper sephora anoth brand lead
luxuri innov advanc digit commerc capabl propel
overal brand growth although opportun advanc e-commerc
across brand encourag lvmh leadership luxuri pioneer
top-lin perform critic stock perform analysi indic
lvmh stock perform highli correl top-lin growth trend
stock correl ebit much lower reflect investor focu
revenu growth trajectori rather margin view lvmh margin mostli
matur level futur earn growth like stem higher sale volum
occasion price increas
thomson cowen
turnaround improv brand posit among chines
consum believ brand opportun penetr chines
luxuri market manag multi-year journey drive innov
product store digit experi achiev higher sale china gold
diamond product custom covet margin compress
recent invest expect start see margin expans
per year reach current level comp
l-msd rang model margin expans benefit watch
jewelri categori margin note estim becom
revenu ebit
beauti market opportun estim global beauti market
lvmh uniqu collect brand drive higher market share gain lvmh
own sephora estim size store global vs
ulta store also prestig brand
parfum christina dior guerlain fenti beauti rihanna compar
sephora select prestig brand portfolio cater higher hhi
believ sephora top prioriti expand footprint global continu
improv e-commerc platform estim sephora top-lin grow hsd
reach compar msd comp lsd
e-commerc opportun e-commerc remain huge opportun luxuri
sector whole lvmh benefit offer omnichannel experi
consum current luxuri sector e-commerc penetr
like penetr climb lvmh oper on-line
platform sevr lvmh sell select brand user experi
current product offer room improv estim lvmh e-
commerc penetr believ lvmh invest scale e-commerc
experi present custom view invest e-commerc
drive increment sale loui vuitton current directli sold third-parti luxuri
strong gener healthi balanc sheet lvmh gener
sale current model increas
sale lvmh robust cash balanc help compani pay debt includ
debt balanc accru transact sustain dividend pay-out
ratio least note given larg size traction lvmh
debt level increas debt/ebitda ratio reach
today
price target deriv use sum-of-the-part given lvmh busi
driven multipl divis across sever categori requir specif oper
margin multipl valuat wine spirit appli price-to-earnings close
peer group averag diageo pernod ricard campari fashion leather
good appli price-to-earnings multipl given loui vuitton
except growth margin watch jewelri appli multipl
bvlgari select retail view price-to-earnings multipl justifi
price-to-earnings multipl sephora line valuat lastli perfum
cosmet appli price-to-earnings multipl slightli oreal este lauder
trade close last three year slight discount due fact
lvmh collect brand includ young brand benefit
near term coronaviru major risk could see mainland china sale declin
close februari march could translat sale declin
china total sale declin could also impact
sale declin per sensit analysi mainland china sale
decreas rang y/i total ebit margin contract
could yield ep dilut assum sale
deriv mainland china note overal sale gener
cowen compani
long-term horizon major risk factor slowdown chines luxuri
consumpt chines consum largest forc behind luxuri growth
shift consum tast style prefer well macroeconom downturn
cowen compani
lvmhincom statementfy decemb fashion leather perfum watch select activ elimin currenc street revenuefx impactcost recur oper incom financi incom financi incom profit minor profit group dilut share margin chg chg margin chg rateconst currenc recur cowen compani compani reportsnot start tiffani includ cowen
cowen compani
note current price
onco stock remain rang bound last year believ fulli reflect
melflufen two upcom catalyst anticip posit top-lin data
phase ocean trial approv melflufen use salvag set
catalyst could significantli improv investor sentiment stock
drive share appreci
anticip fda grant approv melflufen salvag set multipl
myeloma base strong efficaci data horizon trial estim
peak penetr salvag patient us peak sale top-
line data ocean trial compar melflufen vs pomalyst also avail
believ melflufen like show superior could add substanti upsid
stock believ compani receiv limit investor attent rel
melflufen potenti valu oncopeptid also featur best idea see
despit rang approv therapi myeloma larg unmet need novel
therapi beyond line kol view melflufen similar efficaci orr
xpovio better durat respons vs month easier manag
toler profil sinc xpovio approv juli kpti share price doubl
mcap vs oncopeptid
cowen compani fda compani report
toler comparison melflufen xpovio
cowen compani fda compani report
oncopeptid clinic stage biotechnolog compani develop novel agent melflufen
multipl myeloma melflufen prodrug melphalan improv melphalan
safeti efficaci drug current pivot trial horizon salvag myeloma
nda file anticip approv feedback consult
suggest drug address signific unmet medic need patient popul
oncopeptid also sever trial earlier stage patient ocean melflufen vs pomalyst
top-lin data anchor melflufen darzalex melflufen velcad bridg
melflufen renal impair believ ocean particularli import studi
broaden commerci potenti melflufen
nda submiss base horizon data
horizon studi success
melflufen approv salvag mm
horizon studi success
melflufen approv salvag mm
ocean studi show non-inferior
ocean studi show superior
melflufen fail gain approv
ocean studi fail show inferior
pomalyst
base proprietari peptidase-enhanc technolog lead drug melflufen
peptid conjug alkyl develop multipl myeloma drug
shown encourag phase data current pivot phase ii studi horizon
salvag mm addit horizon oncopeptid investig melflufen earlier line
therapi mm well al amyloidosi
anticip posit top-lin data ocean trial compar melflufen vs pomalyst
head-to-head background dexamethason feedback kol suggest
pom dex commonli use combo academ set common
commun practic also head-to-head trial multipl myeloma rare
melflufen outperform pomalyst trial one reason assum out-performance
addit agent ad combin melflufen show superior pomalyst
anticip melflufen gain traction line set upon approv
refer pomalyst us sale y/i estim ww
sale
nda submiss melflufen triple-class refractori diseas base data phase
ii horizon studi track anticip acceler approv
addit top-lin data ocean expect
base model estim peak penetr tripl refractori patient
indic us peak sale market share impli
patient would treat melflufen assum patient would treat
month compar observ melflufen phase ii studi
assum launch price melflufen repres discount compar
brand mm drug market could upsid estim
depend specif label
cowen compani
ocean studi success believ melflufen use expand earlier line
therapi primarili line conserv estim peak us sale
yr indic total peak us sale even multipl yield
mcap vs current valuat valuat provid near
term comp base melflufen approv salvag set
see rel low risk approv probabl success melflufen
salvag set see risk ocean studi probabl success one
kol caution melflufen would show superior rather non-
inferior pomalyst support widespread adopt melflufen well-known
commerci drug like pomalyst melflufen fail show clear superior
pomalyst opportun captur market share may limit even ocean studi
fail believ salvag set label potenti posit data anchor
combo studi combo w/ velcad separ daratumumab final data late
earli provid valuat floor stock
highlight qtnt best european idea qtnt proprietari mosaiq platform
game-chang prospect highli attract transfus diagnost space
furthermor think qtnt share appreci compani advanc pipelin
opportun move toward full-scal commerci mosaiq
firm believ mosaiq potenti disrupt platform transfus
diagnost market attract global compani make
signific stride toward fulli commerci mosaiq platform expect qtnt
achiev number clinic regulatori mileston throughout addit
think recent pullback qtnt share creat compel buy opportun
believ qtnt stock under-valued rel market opportun
compani technolog address qtnt multipl pipelin asset give exposur
substanti opportun outsid donor-test market compani
also earli stage develop molecular disease-screen microarray
success provid qtnt access addit billion-dollar market importantli
mosaiq develop program significantli de-risk partnership
lead diagnost develop
qtnt face number value-cr catalyst beyond summar
figur page expand ih microarray compani start eu field
trial last month expect complet file ce mark approv first
half calendar field studi commenc near term consist
manag comment trial follow shortli eu studi
immin start test like posit qtnt fda file later year
initi sd microarray alreadi receiv ce mark approv submit
clearanc late decemb clearanc come within six month
file expand sd microarray qtnt expect verif
valid effort begin year calendar second quarter eu field
trial slate begin back half year
mosaiq develop significantli de-risk believ share
reward investor gain increas convict current risk profil
discount rate overdon believ mosaiq technolog asset valu increas
dramat front full scale commerci ramp sotp ev/sal analysi
drive price outperform rate
greatest risk call relat qtnt abil develop mosaiq system
time fashion compani sever microarray asset need complet field
trial eu data use regulatori submiss gain
approv commerci concern efficaci qtnt
technolog slippag develop timelin could caus commerci
delay prompt us reduc initi sale ramp assumpt
outperform rate primarili due view compani proprietari mosaiq
platform potenti transform blood transfus diagnost industri mosaiq
proprietari disrupt transfus diagnost platform design autom blood
group diseas screen process donor patient test motto
mosaiq one assay one instrument tell platform boost
effici product test lab hospit
complet eu field trial ce mark
complet initi field trial
achiev development
mileston target
secur contract arc
 market penetr within
receiv regulatori approv achiev
launch mosaiq ahead schedul
secur contract addit test
 market penetr within
faster adopt mosaiq
delay development mileston
failur receiv fda approv ce
failur secur contract arc
 market penetr within
quotient commercial-stag blood transfus diagnost compani engag
reduc health care cost improv patient care develop
commerci revolutionari multiplex microarray assay platform mosiaq
blood group test serolog diseas screen mosaiq expect perform
mandat serolog diseas screen test hiv hepat enabl
detect addit pathogen therebi increas safeti blood suppli
quotient design mosaiq offer breadth diagnost test unmatch
commerci avail transfus diagnost platform
figur upcom clinic regulatori mileston quotient
cowen compani
european field trialseuropean approval/commercializationu field trialsu regulatori approval/commercializationexpand ihcommenc trial januari file ce mark expect commenc imminentlyregulatori submiss could file late sdscompletedreceiv ce mark februari submit decemb decis expect mid sdswill begin field trial late begin field trial late cowen
cowen compani
quotient incom y/i good marginnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmadjust marginnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnm interest/oth expens marginnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmincom tax expens incl net net marginnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmgaap y/i growthnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmadjust y/i growthnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnm basic share mm dilut share march
cowen compani
quotient revenu consum donor growthnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmmosaiq consum patient growthnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmmileston revenu total cowen
believ new manag navig turnaround emerg leading-edg
mixed-sign supplier attract secular vertic semi underpin
lead portfolio gan analog tof igbt see sustain divers
content-driven growth coronaviru uncertainti like weigh near term entir
group stm remain best idea
believ stmicro repres under-valued divers leading-edg mixed-sign
provid tie multipl secular growth vertic auto industri market
includ ada infotain safeti secur mcu sensor digit signal processor
often still mis-character commodit supplier see stm invest
differenti capabl manufactur effici allow compani
address high-growth high-margin applic includ gan fd-soi
mem analog time-of-flight bcd igbt multipl divers company-specif
growth driver clean channel attract valuat see stmicro posit
outgrow peer detail pleas see full best idea note
recent earn note
antiqu view compani impli stmicro remain jack trade
master none overlook tech portfolio/posit includ broad auto
semi suit electrif digit new manag earli track
record consist execut overshadow consum appl exposur unfairli
dismiss given materi invest next-gen tof outsiz growth analog
mem sensor divis upsid potenti consensu revenue/ep assum
stabil forecast return sustain high single-digit
low-teen growth via stabil auto/industri channel special iphon content
mosfet traction huawei/china share gain distribution-friendli strategi
macro improv return broad-bas demand fear broaden
automot design win pipelin smartphon content/unit upsid via iphon
gross margin expans even capac come on-line exit
price valu stock
pt base multipl soxx ep estim
versu consensu equival local share
bear case risk call
industri cyclic low visibl reinvigor demand coronaviru uncertainti
invest facil weigh near-term profit cash flow
potenti risk global automot unit demand lack track record long-term strong
execut histor inabl lower personnel/facil cost
stmicroelectron major supplier semiconductor product emerg growth
area within auto industri iot believ stmicroelectron stm success
navig turnaround posit portfolio diversifi analog digit
semiconductor supplier automot industri market compani recent
reinvigor busi model drive leverag margin expans greater top-
line growth opex control see long-term diversifi growth across stm target
market drive long-term revenue/earn growth close multipl gap compar
peer
autonom electr hybrid vehicl
consist execut drive
continu solid top-line growth
tough stm driven primarili
automot industri near term
quit slow steadi margin expans
result top-lin growth tight opex
control util normal
stronger design win auto
industri result increas market
share result growth
increas content futur model
capital-expenditure invest lead share
gain better margin
issu caus sustain slowdown
automot unit broad-bas mcu/
content loss anoth top
custom weigh revenu
signific near-term invest
manufactur power semi
suppli gener share gain
stmicroelectron global semiconductor compani design develop manufactur
market rang product includ discret standard commod compon
application-specif integr circuit asic analog digit mixed-sign
applic compani construct three segment automot discret group
adg analog mem group microcontrol digit ic group mdg
focus cater high-growth emerg trend auto industri
electron comm equip
convers investor last year even stock
perform well discov mani investor hold see antiqu view
compani believ mani invest commun still view stmicro
european supplier inflat cost structur jack trade master
none product portfolio often overlook compani much improv technolog
portfolio posit heard mani investor remain scar
prior manag poor track record view howev new manag ceo
cfo current role month start
build reput consist execut increasingli reward stm
share valuat addit compani margin structur posit distribution-
friendli non-u supplier could posit stmicro win share china addit trade
continu see stmicro technolog portfolio posit overlook
street particularli compani broad automot semiconductor suit
capabl manag continu showcas meaning design win
leadership posit car electrif digit applic see
fastest area content growth stmicro also continu invest heavili silicon carbid
see instrument electrif strategi remind expect silicon
carbid serv import trend electr vehicl long term
abl achiev cost competit due abil deliv high frequenc switch
withstand significantli higher voltag thu markedli improv electr effici
peer larg disclos design win funnel note
stmicro expect silicon carbid revenu increas least
increasingli divers set custom applic
believ compani consumer/appl exposur inher season
often unfairli dismiss view commod manag invest
materi resourc consum market believ key strateg
technolog advantag could drive outsiz growth time-of-flight serv
perfect exampl remind investor busi play larg role grow
compani analog mem sensor am busi time-
of-flight sensor remain earli adopt curv revenu
estim materi consensu
versu street even lower
number note due relat unit uncertainti forecast return
sustain mid/high singl digit growth three stm segment confid
stem
stabil auto industri market assum materi recoveri
allow content driven growth across stmicro portfolio mcu analog power
semi resum includ ada ev smart meter iot coronaviru present
obviou visibl challeng need monitor
maintain iphon content special imag sensor wireless charg
possibl unit upsid head first iphon launch
increas mosfet win drive continu growth beyond
revenu note adg automot discret group forecast
y/i magnitud could provid alon
huawei china share gain eu-bas non-u supplier particularli gener
purpos mcu stmicro margin structur give abil price aggress
opportun well
distributor-friendli focus strategi versu direct approach
embark texa instrument
continu automot design win includ silicon carbid announc key
macro improv particularli auto industri market allow broad-bas
demand acceler revenu margin util rate normal
iphon launch provid unit upsid devic contain stmicro content
includ special imag sensor newli wireless charg socket
stmicro current trade estim respect
point discount averag broad-bas analog/mcu peer result believ
current level present attract entri point believ current impact
level yet recogn manag turnaround effort long-term secular
driver manag align compani toward note share current trade
near bottom peer group diversifi mid- large-cap supplier
ev/ vs group average price-to-earnings ex-cash basi vs group average
believ due lower margin profil consum revenu concentr risk due
intern manufactur capabl given natur associ high fix cost
uncertain macro backdrop would also point level chart util
consensu estim discount would larger above-street number
present trade rel discount peer anticip stm-specif growth
driver trade closer peer given similarli divers product portfolio tether
ada ev industrial/iot on-going invest target vertic allow address
high-growth/margin applic lead ultim multipl expans
industri cyclic result current cycl last longer
anticip includ potenti coronaviru impact could fail reinvigor demand
would render estim high
invest new technolog manufactur facil includ silicon carbid
capac could weigh profitability/cf
weaker expect content and/or softer sale volum
new technolog like gan time-of-flight sensor may fail take make
continu invest difficult justifi
domicil outsid us fx exposur could result advers benefici
impact result versu domest peer
gross-margin expans oper leverag depend product mix opex
effici given stmicro fix cost structur neg leverag possibl sustain
figur analog mix signal consensu growth estim comparison
cowen compani thomson reuter consensu
figur analog/mix signal forward price-to-earnings ex-cash consensu
figur analog/mix signal ev/ consensu estim
cowen compani thomson reuter consensu
cowen compani thomson reuter consensu
cowen compani estim compani report
 discret group mem sensor digit ic group incom statementmatthew pro-forma result exclud stock base compens intang amort one-tim itemscowen companysourc compani report cowen compani y/i age revenuenot incom statementtot revenu million q/q y/i stm stmicroelectronicsconsolid incom statement million except per share inform periodd q/q y/i age revenu q/q y/i age revenu q/q oper expens good soldgross profitsel gener administr research develop total oper expensesoper incomeoth incom loss incom taxesincom tax provisionpro-forma net incomepro-forma ep dilut incom expens netoper incomeoth netincom taxespro-forma net incometax rate pro-forma non-control interest quarter/quart chang year/year chang research develop averag share outstand dilut revenu sale pro-forma gross profitsel gener administr cowen
see ts offer high qualiti busi exposur intern off-shore
growth next year commod expos busi benefit
differenti rigdirect offer integr ipsco transact
compani gener healthi cash flow debt price target
tenari highli lever intern off-shore spend less commod
price sensit support larg scale develop program
competit commod price sensit market tenari somewhat insul
rigdirect sale model account volum
report see compani guidanc realist
recent upgrad stock target base yield unlev
tenari offer high-qual busi strong cash gener manag
taken step past decad improv busi greater suppli chain
integr expand mill well site rigdirect model busi rel
higher barrier entri compar of busi well posit
benefit improv intern off-shore activ rigdirect offer
temper volatil commod sensit north america recent upgrad
ts sidelin time saw consensu estim
optimist releas compani lower outlook reason
level larg achiev execut recent ipsco acquisit
report ebitda margin guid flat ts expect
exit year margin driven ipsco synergi absenc integr charg
better mix synergi target annual expect
fulli implement year-end ts plan integr ipsco steel make capac
network introduc rigdirect model ipsco custom mix benefit
expect activ grow specif project outsid north america
particularli mexico brazil abu dhabi
target equat yield unlev
ebitda use line industri prior coronaviru
pullback pullback industri group trade yield
assum yield ts would lower target
beyond obviou risk macro oil price drill activ spread
steel make raw materi pipe price import driver margin price
typic move tandem declin oil price increas global could drive
diverg addit investig italian court move trial involv
tenariss chairman ceo well two director alleg improp payment
made brazil compani outsid counsel previous review italian prosecutor
file conclud neither file magistr decis set forth evid
involv director
like ts europ best idea see estim somewhat derisk view
year-end margin target larg achiev ipsco execut
estim remain consensu valuat cash gener attract
downward revis matter upsid project may exist better
mix recoveri pipelogix seem bottom target price
equat unlevel yield estim line industri peer
see busi less volatil typic of stock upsid option
implement section
us total rig count flat
faster-than-expect recoveri
price crude oil
rig count growth
signific reduct octg import
us
prolong period crude oil
tenari lead supplier tube relat servic world energi industri
certain industri applic compani also provid pipe handl stock
distribut servic oil ga energi mechan industri
mm except per unit item unless otherwis note
compani file cowen compani
chg work cap
chg
debt cap
mm except per unit item unless otherwis note
compani file cowen compani
lower market demand us argentina
expect margin line level
ebitda margin progress toward
restructur cost relat ipsco
acquisit
annual run rate synergi kick gradual
reach full benefit
 report adj ebitda miss modest cash flow despit wc releas o/p vs oih like due manag commentari call endors
synergi ipsco improv get margin manag expect pipelogix go higher think base busi benefit higher mix
premium product intern off-shore activ remain strong signal line includ wc benefit year
 announc close ipsco acquisit work capit paid ts sign year master distribut agreement tmk exclus distributor
octg line pipe canada ipsco acquisit help ts diversifi geograph across mid-west northeastern primarili two facil pennsylvania
like ts europ best idea see estim somewhat derisk view year-end margin target larg achiev ipsco execut estim
remain consensu valuat cash geneart attract downward revis matter upsid project may exist better mix recoveri
pipelogix seem bottom execut annual run rate synergi absenc one-tim restructur cost account much progress toward
ebitda margin target see upsid stock ts abl bridg gap restor ipsco break-even improv mix includ greater share premium product
best way model mix premium vs commod pipe sold ts
balanc sheet
manag note call wc would sourc cash
cadenec wc could higher cost inventori ipsco effect
chanc dividend increas futur level would
need ts restor dividend prior level higher
ebitda margin guid flat revenu go
given inclus ipsco move part intern
ipsco acquisit complet step need taken improv
busi break-even downsid risk lever
 rig count
expect one-tim restructur cost relat ipsco
potenti cost
possibl catalyst ispco synergi one-tim cost
reach margin target
much headwind higher cost inventori ipsco much
off-set better premium pipe mix assumpt lower raw
risk margin trump latest announc reinstat
steel tariff argentina
tenari recent award adnoc suppli tubular rig direct
servic five year fair assum revenu equal
roughli mea revenu much increment mea
tot european best idea top pick integr oil space compani
attract transpar project backlog support growth
underpin dividend compound-annual-growth-rate aspir reduc price target
given reduct estim long-term ga price assumpt
tot top pick integr oil space compani articul
cfo goal half increment cash flow sharehold
dividend may grow compound-annual-growth-rate toward high-end peer rang growth
underpin backlog feedstock advantag chemic project upstream
project oil-link price oil project lng project oil price
see growth achiev within steadi capit framework tot also
slowli build renew ga power busi target reduct net
ghg intens energi product
believ market overst tot exposur weak hub ga price
underappreci attract growth backlog due weak lng petchem tot
provid cash flow sensit per /mcf chang nbp hh
ga price sensit modest cfo tot guid
product growth product grew
forecast growth split oil lng
mean limit exposur ga price new product estim compani
also grow petchem margin weak current tot project area
take advantag cheap ethan feedstock therefor competit
tot earn continu demonstr resili ga petchem margin
compress market give credit separ compani outstand
acquisit deckelbaum market perform
sontrach contempl exercis right first refus believ tot walk
away deal close septemb asset cost gener
estim annual tot close deal could modest posit given
yield transact vs long-term averag commod weak
result higher leverag lastli tot announc potenti larg discoveri surinam
adjac boe stabroek block guyana well similar pay size encount
stabroek compani continu delin block year
product growth exceed peer significantli next three year come
highli visibl project materi better cash margin restructur initi
rise lead higher cash return rate outperform
updat africa deal
product ramp-up line
solid execut growth project
capital-expenditure profil line compani
oil price significantli expect
product ramp-up better
better expect execut growth
capital-expenditure peak earlier expect
oil price significantli expect
product ramp-up expect
execut growth project
higher expect capital-expenditure ramp-up
total lead global integr oil/ga compani incorpor franc
compani current oper countri total bboe prove reserv
product mmbo world-wide refin capac roughli mmbd
signific exposur western europ
use averag yield organ arriv new
price target use strip price use flat brent lng nbp price
forecast averag histor refin chemic margin remaind
lower target given reduct long-term ga forecast weak
forecast base proprietari databas upstream downstream
project model project cash flow base country-specif fiscal polici project
fiscal term individu capit cost inform overlaid upstream
declin rate appli upstream cfo in-lin company-specif
product declin rate per barrel upstream sustain capit cost
remain unclear energi sector face structur headwind relat
sustain concern occur discount rate use valu cash flow
hydrocarbon compani could increas reduct expect mid-term commod
price could render forecast high lastli tot declar dividend euro
euro face pressur rel dollar usd-bas dividend
declin euro increas tot equiti base local currenc maintain
similar dividend yield continu pressur euro rel usd could continu
growth underpin project
tot near-term cash flow impact commod weak similar group
howev expect coronaviru impact structur therefor see
attract buy opportun believ tot grow cfo
period like year
viru
tot could insuffici organ year cover sharehold return
stress potenti africa deal close account asset sale
tot expect gener cash howev compani suffici
cover grow dividend organ price deck move forward
figur vs sharehold return mm
cash flow growth underpin tot rich backlog project estim
compani project startup/ramp-up growth includ
algeria/ghana also account lost libyan oil product
current offlin growth off-set natur declin
compani sanction anoth group project past coupl year
gener oil tot see product
grow compound-annual-growth-rate period stabil believ compani
backlog continu support growth project link oil-pric appendix
full list project
fx factor consid given dividend yield
tot dividend yield us list european list share shown minim differ
go back period particularli euro
weaken rel dollar tot declar dividend euro weaker euro
translat lower dividend growth us sharehold equilibrium dividend
yield amidst fx volatil risk mind
figur chang equiti vs fx
equiti chang
figur new product product kbo
figur recent sanction project product kbo
figur potenti project product kbo
import disclosur inform relat cowen washington research group
